<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> NOVO NORDISK A S (Form: 20-F, Received: 02/09/2017 07:18:25) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_IDENTITY_OF_PERSONNEL **FIS_PART_I_2 **FIS_OFFER_STATISTICS **FIS_KEY_INFORMATION **FIS_COMPANY_INFORMATION **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_OPERATING_AND_FINANCIAL_REVIEW **FIS_LIQUIDITY_CAPITAL **FIS_DIRECTORS_AND_OFFICERS **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_FINANCIAL_DATA **FIS_LISTING **FIS_ADDITIONAL_INFORMATION **FIS_MARKET_RISK **FIS_OTHER_SECURITIES **FIS_PART_II **FIS_DEFAULTS **FIS_PART_II_2 **FIS_MATERIAL_MODIFICATIONS **FIS_CONTROL_AND_PROCEDURES **FIS_AUDIT_COMMITTEE_EXPERT **FIS_CODE_OF_ETHICS **FIS_ACCOUNTANT_FEES **FIS_EXEMPTIONS_FROM_LISTING **FIS_PURCHASES_OF_EQUITY **FIS_CHANGE_IN_ACCOUNTANT **FIS_CORPORATE_GOVERNANCE **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_III **FIS_FINANCIAL_STATEMENTS **FIS_PART_III_2 **FIS_FINANCIAL_STATEMENTS_2 **FIS_FINANCIAL_STATEMENTS_3 **FIS_FINANCIAL_STATEMENTS_4 **FIS_FINANCIAL_STATEMENTS_5 **FIS_FINANCIAL_STATEMENTS_6 **FIS_EXHIBITS **FIS_AUDITORS_OPINION **FIS_SIGNATURES FIS_EXHIBIT_11 FIS_EXHIBIT_12 FIS_EXHIBIT_12_2 FIS_EXHIBIT_13 FIS_EXHIBIT_15 ">
<META NAME="DETECTED PAGES" CONTENT="67">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F20F_020917_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	UNITED
	STATES SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Washington, D.C. 20549
</U>
</B>
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM 20-F
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(Mark One)
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
	&#9744;
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	REGISTRATION STATEMENT PURSUANT
	TO SECTION 12(b) OR (g)
</FONT>
	OF THE SECURITIES EXCHANGE ACT OF 1934
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	OR
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
	&#9746;
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ANNUAL REPORT PURSUANT TO
	SECTION 13 OR 15(d) OF THE
</FONT>
	SECURITIES EXCHANGE ACT OF 1934
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	For the fiscal year ended December 31,
	2016
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.75IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	OR
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
	&#9744;
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	TRANSITION REPORT PURSUANT
	TO SECTION 13 OR 15(d) OF THE
</FONT>
	SECURITIES EXCHANGE ACT OF 1934
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	OR
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
	&#9744;
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SHELL COMPANY REPORT PURSUANT
	TO SECTION 13 OR 15(d) OF THE
</FONT>
	SECURITIES EXCHANGE ACT OF 1934
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Commission File Number: 333-82318
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 16PT">
<B>
	NOVO NORDISK
	A/S
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Exact name of Registrant as specified in
	its charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Not applicable
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	The Kingdom of Denmark
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	(Translation of Registrant&rsquo;s
	name into English)
</P>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	(Jurisdiction of incorporation
	or organization
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Novo All&eacute;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	DK-2880 Bagsv&aelig;rd
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Denmark
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(Address of principal executive offices)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Jesper Brandgaard
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Executive Vice President and Chief Financial
	Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Tel: +45 4444 8888
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	E-mail: jbr@novonordisk.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Novo All&eacute;, DK-2880 Bagsv&aelig;rd,
	Denmark
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	(Name, Telephone, E-mail and Address of
	Company Contact Person)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Securities registered or to be registered pursuant to Section
	12(b) of the Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title of each class:
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name of each exchange on which registered:
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	B shares, nominal value DKK 0.20 each
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	New York Stock Exchange*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	American Depositary Receipts,
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	New York Stock Exchange
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	each representing one B share&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	* Not for trading, but only in connection with the registration
	of American Depositary Receipts, pursuant to the requirements of the Securities and Exchange Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Securities registered or to be registered pursuant to Section
	12(g) of the Act: None
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Securities for which there is a reporting obligation pursuant
	to Section 15(d) of the Act: None
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate the number of outstanding shares of each of the issuer&rsquo;s
	classes of capital or common stock as of the close of the period covered by the Annual Report:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="WIDTH: 40%; FONT-SIZE: 10PT; PADDING-LEFT: 30PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A shares, nominal value DKK 0.20 each:
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	537,436,000
</FONT>
</TD>
<TD STYLE="WIDTH: 45%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 30PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	B shares, nominal value DKK 0.20 each:
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,012,564,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is a well-known seasoned
	issuer, as defined in Rule 405 of the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
	&#9746;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9; No
</FONT>
	&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If this report is an annual or transition report, indicate by
	check mark if the registrant is not required to file reports to Section 13 or 15(d) of the Securities Exchange Act of 1934.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9; No
</FONT>
	&#9746;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the Registrant (1) has filed
	all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
	for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements
	for the past 90 days,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
	&#9746;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9; No
</FONT>
	&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant has submitted
	electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
	to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
	registrant was required to submit and post such files).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9; No
</FONT>
	&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, or a non-accelerated filer. See
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	definition of &ldquo;accelerated filer and large accelerated
	filer&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Large
	accelerated filer
</FONT>
	&#9746;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accelerated
	filer
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-accelerated
	filer
</FONT>
	&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark which basis of accounting the registrant
	has used to prepare the financial statements included in this filling:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S.
	GAAP
</FONT>
	&#9744;
</TD>
<TD NOWRAP STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	International
	Financial Reporting Standards as issued
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER">
	Other &#9744;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	by
	the International Accounting Standards Board
</FONT>
	&#9746;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If &ldquo;Other&rdquo; has been checked in response to the previous
	question, indicate by check mark which financial statement item the registrant has elected to follow:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item
	17
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item 18
</FONT>
	&#9744;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If this is an annual report, indicate by check mark whether
	the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9;&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
	&#9746;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE; COLOR: #009FDA">
	Table
	of CONTENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
<FONT STYLE="FONT-SIZE: 12PT">
	Table
	of CONTENTS
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD COLSPAN="3">
<A HREF="#F20F_020917_HTM_A_001">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	INTRODUCTION
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_001">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF">
<TD COLSPAN="3">
<A HREF="#F20F_020917_HTM_A_002">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	Part I
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 1
</FONT>
</A>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT; WIDTH: 78%">
<A HREF="#F20F_020917_HTM_A_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	IDENTITY
	OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS
</FONT>
</A>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; WIDTH: 10%">
<A HREF="#F20F_020917_HTM_A_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_004">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 2
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_004">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OFFER
	STATISTICS AND EXPECTED TIMETABLE
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_004">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 3
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	KEY
	INFORMATION
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 4
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	INFORMATION
	ON THE COMPANY
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_007">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 4A
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_007">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unresolved
	staff comments
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_007">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_008">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 5
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_008">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OPERATING
	AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_008">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_009">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 6
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_009">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	DIRECTORS,
	EXECUTIVE MANAGEMENT AND EMPLOYEES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_009">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	18
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_010">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 7
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_010">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	MAJOR
	SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_010">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	20
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_011">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 8
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_011">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FINANCIAL
	INFORMATION
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_011">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	23
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_012">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 9
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_012">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	THE
	OFFER AND LISTING
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_012">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	23
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_013">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 10
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_013">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ADDITIONAL
	INFORMATION
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_013">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	25
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_014">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 11
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_014">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	QUALITATIVE
	AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_014">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_015">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 12
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_015">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	DESCRIPTION
	OF SECURITIES OTHER THAN EQUITY SECURITIES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_015">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_016">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 12A
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_016">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	DEBT
	SECURITIES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_016">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_017">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 12B
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_017">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	WARRANTS
	AND RIGHTS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_017">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_018">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 12C
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_018">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OTHER
	SECURITIES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_018">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_019">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 12D
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_019">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	American
	DEpositary shares
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_019">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF">
<TD COLSPAN="3">
<A HREF="#F20F_020917_HTM_A_020">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	Part II
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_021">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 13
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_021">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	DEFAULTS,
	DIVIDEND ARREARAGES AND DELINQUENCIES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_021">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	33
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_022">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 14
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<A HREF="#F20F_020917_HTM_A_022">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	MATERIAL
	MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_022">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	33
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_023">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 15
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_023">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CONTROLS
	AND PROCEDURES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_023">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	33
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_024">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16A
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_024">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AUDIT
	COMMITTEE FINANCIAL EXPERTS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_024">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_025">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16B
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_025">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CODE
	OF ETHICS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_025">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_026">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16C
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_026">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PRINCIPAL
	ACCOUNTANT FEES AND SERVICES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_026">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_027">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16D
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_027">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	EXEMPTIONS
	FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_027">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	35
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_028">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16E
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<A HREF="#F20F_020917_HTM_A_028">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PURCHASES
	OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_028">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	36
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_029">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16F
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_029">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	change
	in registrant&rsquo;s certifying accountant
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_029">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	37
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_030">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16G
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_030">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Corporate
	governance
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_030">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	37
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_031">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 16H
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_031">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	MINE
	SAFETY DISCLOSURE
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_031">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	39
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF">
<TD COLSPAN="3">
<A HREF="#F20F_020917_HTM_A_032">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	Part III
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_033">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 17
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_033">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FINANCIAL
	STATEMENTs
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_033">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	40
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_034">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 18
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_034">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FINANCIAL
	STATEMENTs
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_034">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	40
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F20F_020917_HTM_A_035">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM 19
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -56.7PT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 56.7PT">
<A HREF="#F20F_020917_HTM_A_035">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	EXHIBITS
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_035">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	44
</FONT>
</A>
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT VERDANA, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD COLSPAN="3">
<A HREF="#F20F_020917_HTM_A_036">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SIGNATURES
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
<A HREF="#F20F_020917_HTM_A_036">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	47
</FONT>
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	INTRODUCTION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 70.9PT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_001">
</A>
	INTRODUCTION
</FONT>
</TD>
<TD>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In this Form 20-F the terms &lsquo;the
	Company&rsquo;, &lsquo;Novo Nordisk&rsquo; and &lsquo;the Group&rsquo; refer to the parent company Novo Nordisk A/S together with
	its consolidated subsidiaries. The term &lsquo;Novo Nordisk A/S&rsquo; is used when addressing issues specifically related to this
	legal entity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Throughout this Form 20-F the Company
	incorporates information on the various items by reference to its statutory
<I>
	Annual Report 2016 and Annual Report 2015
</I>
	,
	i.e. including the financial statements of Novo Nordisk A/S (hereafter
<I>
	&ldquo;Annual Report 2016&rdquo;
</I>
	and
<I>
	&ldquo;Annual
	Report 2015&rdquo;
</I>
	, respectively). Therefore the information in this Form 20-F should be read in conjunction with our
<I>
	Annual
	Report 2016
</I>
	and
<I>
	Annual Report 2015
</I>
	, which were furnished to the SEC on Form 6-K on February 9, 2017 and on February
	10, 2016, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company publishes its financial statements
	in Danish kroner (DKK).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Forward-looking statements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The information set forth in this Form
	20-F contains forward-looking statements as the term is defined in the U.S. Private Securities Litigation Reform Act of 1995.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Words such as &lsquo;believe&rsquo;, &lsquo;expect&rsquo;,
	&lsquo;may&rsquo;, &lsquo;will&rsquo;, &lsquo;plan&rsquo;, &lsquo;strategy&rsquo;, &lsquo;prospect&rsquo;, &lsquo;foresee&rsquo;,
	&lsquo;estimate&rsquo;, &lsquo;project&rsquo;, &lsquo;anticipate&rsquo;, &lsquo;can&rsquo;, &lsquo;intend&rsquo;, &lsquo;target&rsquo;
	and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify
	forward-looking statements. Examples of such forward-looking statements include, but are not limited to:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 11.35PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	statements of targets, plans, objectives or goals for future operations, including those related
	to Novo Nordisk&rsquo;s products, product research, product development, product introductions and product approvals as well as
	cooperation in relation thereto
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 11.35PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	statements containing projections of or targets for revenues, costs, income (or loss), earnings
	per share, capital expenditures, dividends, capital structure, net financials and other financial measures
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 11.35PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	statements regarding future economic performance, future actions and outcome of contingencies such
	as legal proceedings
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 11.35PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	statements regarding the assumptions underlying or relating to such statements.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	With reference to our
<I>
	Annual Report
	2016
</I>
	and
<I>
	Annual Report 2015
</I>
	, examples of forward-looking statements can be found under the headings, &lsquo;2016 performance
	and 2017 outlook&rsquo; in our
<I>
	Annual Report 2016
</I>
	and &lsquo;2015 performance and 2016 outlook&rsquo; in our
<I>
	Annual Report
	2015
</I>
	, and elsewhere.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These statements are based on current plans,
	estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general
	and specific. Novo Nordisk cautions that a number of important factors could cause actual results to differ materially from those
	contemplated in any forward-looking statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Factors that may affect future results
	include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency
	exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions
	of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven
	price decreases for Novo Nordisk&rsquo;s products, introduction of competing products, reliance on information technology, Novo
	Nordisk&rsquo;s ability to successfully market current and new products, exposure to product liability and legal proceedings and
	investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property
	protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to
	ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and
	expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<EFX_IDENTITY_OF_PERSONNEL>
<A NAME="FIS_IDENTITY_OF_PERSONNEL"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 1 IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For an overview of some, but not all,
	of the risks that could adversely affect our results or the accuracy of forward-looking statements in this document, reference
	is made to the overview of risk factors in our
<I>
	Annual Report 2016
</I>
	&lsquo;Risk management&rsquo; on pages 40-43.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Unless required by law, Novo Nordisk is
	under no duty and undertakes no obligation to update or revise any forward-looking statement after the date of this document, whether
	as a result of new information, future events or otherwise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Enforceability of civil liabilities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company is a Danish corporation and
	substantially all of its directors and officers, as well as certain experts named herein, are non-residents of the United States.
	A substantial portion of the assets of the Company, its subsidiaries and such persons are located outside the United States. As
	a result, it may be difficult for shareholders of the Company to effect service within the United States upon directors, officers
	and experts who are not residents of the United States or to enforce judgments in the United States. In addition, there can be
	no assurance as to the enforceability in Denmark against the Company or its respective directors, officers and experts who are
	not residents of the United States, or in actions for enforcement of judgments of United States courts, of liabilities predicated
	solely upon the federal securities laws of the United States.
</P>
</EFX_IDENTITY_OF_PERSONNEL>
</EFX_PART_I>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I_2"></A>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #001965">
<B>
<A NAME="F20F_020917_HTM_A_002">
</A>
	PART I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_003">
</A>
	ITEM 1
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	IDENTITY
	OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_OFFER_STATISTICS>
<A NAME="FIS_OFFER_STATISTICS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_004">
</A>
	ITEM 2
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	OFFER
	STATISTICS AND EXPECTED TIMETABLE
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
</EFX_OFFER_STATISTICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_KEY_INFORMATION>
<A NAME="FIS_KEY_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_005">
</A>
	ITEM 3
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	KEY
	INFORMATION
</FONT>
</TD>
</TR>
</TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; COLOR: #001965">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SELECTED
	FINANCIAL DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	Selected
	financial data
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	IFRS figures in DKK millions, except share and American Depositary Receipts (&lsquo;ADR&rsquo;) data
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	2012
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Income statement data
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Net sales
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	78,026
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	83,572
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	88,806
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	107,927
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	111,780
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Operating profit from continuing operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	29,474
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	31,493
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	49,444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Operating profit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	29,474
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	31,493
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	49,444
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Net profit from continuing operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	21,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	25,184
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	37,925
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Net profit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	21,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	25,184
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	37,925
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Earnings per share
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Earnings per share/ADR
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	7.82
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	9.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	10.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	13.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	14.99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Diluted earnings per share/ADR
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	7.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	9.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	10.07
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	13.52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	14.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Balance sheet data
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	65,669
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	70,337
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	77,062
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	91,799
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	97,539
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Net assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	40,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	42,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	40,294
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	46,969
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	45,269
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Capital stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	560
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	510
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Treasury stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(11
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	(9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Dividends per share/ADR*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	3.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	4.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	6.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	7.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Dividends per share/ADR in USD*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	0.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	0.83
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	0.82
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	0.94
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1.08
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; BACKGROUND-COLOR: WHITE">
	Number of shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,650
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	2,550
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	*)
	Total dividend for the financial year 2016 including proposed final dividend of DKK 4.60 per share and interim dividend paid in
	August 2016 of DKK 3.00 per share. For USD translation the exchange rate at December 30, 2016 from Danmarks Nationalbank (The
	Central Bank of Denmark) is used (USD 1 = DKK 7.05)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 3 KEY INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to &lsquo;Consolidated
	financial, social and environmental statements 2016&rsquo;, pages 57-106 in our
<I>
	Annual Report 2016
</I>
	for further data.
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	Exchange
	rate information
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following tables set forth, for the
	calendar periods indicated, certain information concerning Danmarks Nationalbank&rsquo;s daily official exchange rates for U.S.
	dollars in terms of Danish kroner expressed in DKK per USD 1.00. These rates closely approximate the noon buying rate for Danish
	kroner for cable transfers in New York City as announced by the Federal Reserve Bank of New York for customs purposes on the relevant
	dates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 41%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	DKK per USD
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 16%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	Monthly
<BR>
	average rate
</FONT>
</TD>
<TD STYLE="WIDTH: 16%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 14.2PT 0PT 0; TEXT-ALIGN: CENTER">
	Period end rate
</P>
</TD>
<TD STYLE="WIDTH: 14%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	High
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Low
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2012
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	5.76
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.66
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.15
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.53
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2013
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	5.61
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.41
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.84
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.40
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	5.65
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.12
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.12
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	5.35
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	6.76
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.83
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.08
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.18
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	6.75
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.05
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.17
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.43
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Last six months
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	August 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.69
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.71
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.56
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	September 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.68
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.69
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.59
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	October 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.80
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.84
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.63
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	November 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.00
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.05
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.71
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	December 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.05
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.17
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.91
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	January 2017
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.92
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	7.16
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.92
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	February 2017 (through February 1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.89
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.89
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	6.89
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On February 1, 2017, the latest available date, the Danmarks
	Nationalbank&rsquo;s daily official exchange rate was 6.89.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #002060; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Capitalization and indebtedness
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #002060">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #002060; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Reasons for the offer and use of proceeds
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #002060; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Risk factors
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #002060">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For information on risk factors, reference
	is made to our
<I>
	Annual Report 2016
</I>
	&lsquo;Risk management&rsquo; on pages 40-43. In addition to the risks included in &lsquo;Risk
	management&rsquo; in our
<I>
	Annual Report 2016
</I>
	, we may be subject to other material risks that as of the date of this report
	are not currently known to us or that we deem less material at this point in time. Such risks include the risk that our IT security
	set-up may not prevent all forms of unauthorized access to our computer network systems for purposes of misappropriating assets,
	trade secrets or sensitive information, and the risks arising from current macro-economic conditions including the impact of fiscal
	austerity measures on our customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	PCAOB
<FONT STYLE="TEXT-TRANSFORM: NONE">
	inspection of our independent auditors
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	With Novo Nordisk being a public company
	listed in the United States, our independent public accounting firm, PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab
	(CVR no 3377 1231), is registered with the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) and therefore required
	to undergo regular PCAOB inspections to assess the registered accounting firm&rsquo;s compliance with United States law and professional
	standards in connection with its audits of financial statements filed with the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_KEY_INFORMATION>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_COMPANY_INFORMATION>
<A NAME="FIS_COMPANY_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_006">
</A>
	ITEM 4
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	INFORMATION
	ON THE COMPANY
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	History and development of the company
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk was formed in 1989 by a merger
	of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. Novo Industri A/S was the continuing company and its name
	was changed to Novo Nordisk A/S. The business activities of Nordisk Gentofte were established in 1923 by August Krogh, H. C. Hagedorn
	and A. Kongsted, and the business activities of Novo Industri A/S were established in 1925 by Harald and Thorvald Pedersen. The
	business of both companies from the beginning was production and sale of insulin for the treatment of diabetes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November 2000 Novo Nordisk spun off
	its industrial enzyme division into a separate business, Novozymes A/S. In March 2015 an initial public offering of NNIT A/S, an
	international IT service provider, was completed whereby, Novo Nordisk A/S divested almost 75% of its interest held in NNIT A/S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s B shares are listed
	on Nasdaq Copenhagen (Novo-B). Its American Depositary Receipts (ADR) are listed on the New York Stock Exchange (NVO).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 30%">
	Legal name:
</TD>
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 65%">
	Novo Nordisk A/S
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Commercial name:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Novo Nordisk
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Domicile:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Novo All&eacute;, DK-2880 Bagsv&aelig;rd,
	Denmark
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Tel: &#9;+45 4444 8888
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Fax: &#9;+45 4449 0555
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Website: &#9;novonordisk.com
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	(The contents of this website are not incorporated by
	reference into this Form 20-F.)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Date of incorporation:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	November 28, 1931
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Legal form of the Company:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	A Danish limited liability company
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Legislation under which
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	the Company operates:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Danish law
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD>
	Country of incorporation:
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Denmark
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Important events in 2016
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Reference is made to &lsquo;Accomplishments and results 2016&rsquo;,
	pages 1-15 in our
<I>
	Annual Report 2016
</I>
	for a description of important events in 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Capital expenditure in 2016, 2015 and 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total net capital expenditure for property,
	plant and equipment was DKK 7.1 billion in 2016 compared with DKK 5.2 billion in 2015 and DKK 4.0 billion in 2014. Net capital
	expenditure was primarily related to investments in a new production facility for a range of diabetes active pharmaceutical ingredients,
	a new diabetes care filling capacity and an expansion of the manufacturing capacity for biopharmaceutical products. The investments
	were financed with cash flow from operating activities. Apart from the divestment of NNIT A/S in 2015, no significant divestments
	took place in the period from 2014&ndash;2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Capital expenditure is expected to be around
	DKK 10.0 billion in 2017, primarily related to investments in additional capacity for active pharmaceutical ingredient production
	within diabetes care, a capacity expansion of the diabetes care filling and an expansion of the manufacturing capacity for biopharmaceutical
	products. The investments are expected to be financed with cash flow from operating activities.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Public takeover offers
	in respect of the Company&rsquo;s shares
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	No such offers occurred during 2016 or
	2017 to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Business overview
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk is a global healthcare company
	and a world leader in diabetes care. The Company has one of the broadest diabetes product portfolios in the industry, including
	new generation insulin, a full portfolio of modern insulin as well as a human once-daily GLP-1 analog. In addition, Novo Nordisk
	also has a leading position within haemophilia care and growth hormone therapy, and Novo Nordisk&rsquo;s first product to treat
	obesity, Saxenda
<SUP>
	&reg;
</SUP>
	, was launched in the United States in April 2015 and has now been launched in an additional 14
	countries. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients,
	the medical profession and the society. Headquartered in Denmark, Novo Nordisk employs approximately 42,500 employees in 75 countries
	and markets its products in more than 180 countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Reference is made to the section &lsquo;Our business&rsquo;
	on pages 16-43 in our
<I>
	Annual Report 2016.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Segment information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk is engaged in the discovery,
	development, manufacturing and marketing of pharmaceutical products and has two business segments: (i) diabetes and obesity care
	and (ii) biopharmaceuticals. The diabetes and obesity care segment covers insulin, GLP-1, other protein-related products (such
	as glucagon, protein-related delivery systems and needles) and oral anti-diabetic drugs. The biopharmaceuticals segment covers
	the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Seasonality
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Sales of individual products in individual
	markets may be subject to fluctuations from quarter to quarter. However, the Company&rsquo;s consolidated operating results have
	not been subject to significant seasonality.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Raw materials
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The impact on the overall profitability
	of Novo Nordisk from variations in raw material prices is unlikely to be significant. There is no raw material supply shortage
	that is expected to significantly impact the Company&rsquo;s ability to supply any significant market. The Company&rsquo;s production
	is largely based on common and readily available raw materials with relatively low price volatility. Certain specific raw materials
	are, however, less available. For these raw materials, it is the policy of Novo Nordisk to develop close and long-term relationships
	with key suppliers as well as to secure at least dual sourcing whenever possible and when relevant operate with a predefined minimum
	safety level of raw material inventories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Market and competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s insulin and other
	pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility
	for specific geographical areas. In 2016, Novo Nordisk reported based on a regional structure comprising the USA, Europe, International
	Operations, China and Pacific. However, a new regional structure was announced in September 2016. The new regional structure for
	reporting will be implemented in January 2017. The new regional structure is comprised of two main commercial units: North America
	(the United States and Canada) and International Operations. International Operations will cover all countries except for North
	America and will be organised in the following five regions: Europe; Latin America; AAMEO (Africa, Asia, Middle East &amp; Oceania);
	Japan &amp; Korea; and Region China. For 2016, the most important markets are the United States, China, Japan and the major European
	countries. In addition there is an increasing contribution to Novo Nordisk&rsquo;s total sales from the following markets: Brazil,
	India, Turkey, Algeria, Saudi Arabia, Iran, Argentina and Russia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Market conditions within the pharmaceutical
	industry continue to change, including efforts by both private and governmental entities to reduce or control costs generally and
	in specific therapeutic areas.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Historically, the market for insulin has been more sensitive
	to the quality of products and services than to price. Most of the countries in which Novo Nordisk sells insulin subsidize or control
	pricing and in most markets insulin and GLP-1 are prescription drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2016, payers globally have managed the
	cost of diabetes care by exerting pressure on the prices of Novo Nordisk&rsquo;s products and competitors have tried to capture
	market share from Novo Nordisk. In spite of this, Novo Nordisk maintained the leading position in the overall diabetes care market
	through the quality and innovative value of the company&rsquo;s diabetes care products. In the United States, pharmacy benefit
	managers and health plans have continued to leverage their increasing size and control to demand higher rebates which has impacted
	the price level and overall value of the market. Moreover, actions by companies in the diabetes care market to increase list prices
	have been lower than prior years and the introduction of new products by competitors has further increased the downward pressure
	on prices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company enters into numerous contracts
	with customers, suppliers, agents and industry partners. Some of the most important contracts include: commercial contracts with
	pharmacy benefit managers, health plans and healthcare providers, in- and out-licensing of patent rights, large tender orders
	and long-term sub-supplier agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Due to the increasing number of people
	with diabetes, the pharmaceutical market for treatment of diabetes continues to grow. Several of the major international pharmaceutical
	companies have entered the diabetes market, specifically in the area of oral products for treatment of type 2 diabetes. In the
	global insulin market, Novo Nordisk, Sanofi and Eli Lilly are the most significant companies measured by market share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The roll-out of
	Tresiba
<SUP>
	&reg;
</SUP>
	(insulin degludec), the once-daily new-generation insulin, continues and the product has now been
	launched in 52 countries. In the United States, where Tresiba
<SUP>
	&reg;
</SUP>
	was launched broadly in January 2016, early
	feedback from patients and prescribers is encouraging, and the product has achieved wide commercial and Medicare Part D
	formulary coverage. By the end of 2016, Tresiba
<SUP>
	&reg;
</SUP>
	had captured a 5.5% market share of the United States basal
	insulin market measured in weekly total prescriptions. In Japan, where Tresiba
<SUP>
	&reg;
</SUP>
	was launched in March 2013
	with similar reimbursement as insulin glargine U100, its share of the basal insulin market has grown steadily, and
	Tresiba
<SUP>
	&reg;
</SUP>
	has now captured 39% of the basal insulin market measured by monthly value market share. Similarly,
	Tresiba
<SUP>
	&reg;
</SUP>
	has shown solid penetration in other markets with reimbursement at a similar level to insulin
	glargine U100, whereas penetration remains modest in markets with restricted market access.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Xultophy
<SUP>
	&reg;
</SUP>
	(IDegLira),
	a once-daily single-injection combination of insulin degludec (Tresiba
<SUP>
	&reg;
</SUP>
	) and liraglutide
	(Victoza
<SUP>
	&reg;
</SUP>
	), has now been marketed in nine countries, and launch activities are generally progressing as
	planned. In November 2016, Xultophy
<SUP>
	&reg;
</SUP>
	100/3.6 was approved by the U.S. Food and Drug Administration
	(&ldquo;FDA&rdquo;) and Novo Nordisk plans to launch the product in the United States in the first half of 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Ryzodeg
<SUP>
	&reg;
</SUP>
	, a soluble
	formulation of insulin degludec and insulin aspart, has now been marketed in 10 countries, and feedback from patients and
	prescribers is encouraging.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Patents
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To maintain and expand competitiveness,
	Novo Nordisk strives for the strongest possible protection for those inventions that are created during the development of new
	products. Novo Nordisk anticipates that the expiration of certain patents could impact sales within the coming years. However,
	through continued investments in research and development, Novo Nordisk strives to bring novel and innovative products to the market
	and thereby sustain strong patent protection in the future, as new generations of products replace currently marketed products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For patent information on all Novo Nordisk&rsquo;s
	marketed products, reference is made to the section &lsquo;Consolidated social statement&rsquo; on page 98 in our
<I>
	Annual Report
	2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the compound patents discussed in &lsquo;Consolidated
	social statement&rsquo; on page 101 in our
<I>
	Annual Report 2016
</I>
	, Novo Nordisk&rsquo;s key delivery devices are protected by
	several patents of which the first will expire in January 2019.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the following section the patent protection
	of our key products within each business segment is considered. For key products with recent patent expiration or with patent expiration
	occurring within the coming years, geographical sales splits are provided and factors that may influence the potential impact of
	competitive product launches are discussed. Note that in addition to the compound patents mentioned, Novo Nordisk has, like other
	companies engaged in production based upon recombinant DNA technology, obtained licenses under various patents which entitle Novo
	Nordisk to use processes and methods of manufacturing covered by such patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	Sales
	of key products with recent or upcoming patent expiration:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Product
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Total sales in
<BR>
	2016 (in DKK
<BR>
	million)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	USA
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Europe
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	International
<BR>
	Operations
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Region China
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Pacific
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 34%; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	NovoLog
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	19,945
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	56
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; TEXT-ALIGN: LEFT">
	NovoLog
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
	Mix /NovoMix
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	10,482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Prandin
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
	/NovoNorm
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	NovoSeven
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	9,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Norditropin
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	8,770
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Vagifem
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	2,995
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<I>
	Patent situation of
	key diabetes care products
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total sales of NovoLog
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
	were DKK 19,945 million in 2016 (DKK 20,720 million in 2015). The drug compound patent for NovoLog
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
	has expired. The patent in Japan expired in December 2010 and the European patent expired in August 2011. In the United States
	NovoLog
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
	was patent protected until December 2014. In addition to the drug compound patent,
	Novo Nordisk holds a formulation patent on NovoLog
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
	, which provides coverage until June
	2017 in all major markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total sales of NovoLog
<SUP>
	&reg;
</SUP>
	Mix/NovoMix
<SUP>
	&reg;
</SUP>
	were DKK 10,482 million in 2016 (DKK 11,144 million in 2015). The drug compound patent for NovoLog
<SUP>
	&reg;
</SUP>
	Mix /NovoMix
<SUP>
	&reg;
</SUP>
	has expired in most countries. In Japan the drug compound patent expired in June 2014, in the United States the drug compound patent
	expired in December 2014 and in Europe the drug compound patent expired on a country-by-country basis throughout 2014 and into
	2015. In addition, Novo Nordisk holds a formulation patent on NovoLog
<SUP>
	&reg;
</SUP>
	Mix /NovoMix
<SUP>
	&reg;
</SUP>
	in the United
	States, which provides coverage until December 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Today, biosimilar versions of
	insulin can be approved in the United States via the 505(b)(2) pathway, and in the future the 351(k) pathway in the Public Health
	Service Act is also anticipated to be applicable. In the EU, a biosimilar pathway and guidelines are available for insulins, and
	the guideline for biosimilar products issued in Japan is also relevant for insulins. We believe that the formulation patent for
	NovoLog&reg;/NovoRapid
<SUP>
	&reg;
</SUP>
	in all major markets and for NovoLog
<SUP>
	&reg;
</SUP>
	Mix /NovoMix
<SUP>
	&reg;
</SUP>
	in the
	United States makes it challenging to develop a biosimilar version of these compounds prior to the expiry of the aforementioned
	patents without infringing Novo Nordisk&rsquo;s intellectual property. In China, biosimilars to NovoRapid
<SUP>
	&reg;
</SUP>
	and NovoMix
<SUP>
	&reg;
</SUP>
	have been filed for regulatory approval by a local competitor. Meanwhile, no biosimilar to either NovoLog
<SUP>
	&reg;
</SUP>
	/NovoRapid
<SUP>
	&reg;
</SUP>
	or NovoLog
<SUP>
	&reg;
</SUP>
	Mix /NovoMix
<SUP>
	&reg;
</SUP>
	is currently being tested in clinical trials for the triad markets of the
	EU, the United States and Japan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total sales of Prandin
<SUP>
	&reg;
</SUP>
	/NovoNorm
<SUP>
	&reg;
</SUP>
	,
	an oral antidiabetic drug, were DKK 1,597 million in 2016 (DKK 1,688 million in 2015) and together with other oral antidiabetic
	products of DKK 107 million in 2016 (DKK 134 million in 2015), the total sales of all oral antidiabetic products (OAD) were DKK
	1,704 million in 2016 (DKK 1,822 million in 2015). Prandin
<SUP>
	&reg;
</SUP>
	/NovoNorm
<SUP>
	&reg;
</SUP>
	is no longer protected as the
	drug compound patent has expired in all key markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In Europe, generic copies of NovoNorm
<SUP>
	&reg;
</SUP>
	were first introduced in Germany in 2010 and introductions of generic copies have subsequently been observed, e.g. in France, Italy,
	Spain and Belgium. During 2012, generic competition significantly reduced our European sales of NovoNorm
<SUP>
	&reg;
</SUP>
	with most
	of the reduction, varying from country to country, occurring in the first 12 months following the introduction of generic competition.
	Our European sales of NovoNorm
<SUP>
	&reg;
</SUP>
	continued to erode during 2016 due to generic competition, and we expect this trend
	to continue during 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the United States, generic copies of
	Prandin
<SUP>
	&reg;
</SUP>
	were approved in July 2013 from respectively Caraco and Paddock, and Novo Nordisk has since then and throughout
	2016 seen a significant decline in sales of Prandin
<SUP>
	&reg;
</SUP>
	in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In China, NovoNorm
<SUP>
	&reg;
</SUP>
	has been exposed to generic
	competition for several years without significantly impacting our sales. Therefore, we do not expect a significant decline in NovoNorm
<SUP>
	&reg;
</SUP>
	sales in China in the short term due to generic competition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<I>
	Patent situation of
	key biopharmaceuticals products
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total sales of NovoSeven
<SUP>
	&reg;
</SUP>
	were DKK 9,492 million in 2016 (DKK 10,064 million in 2015). While the drug compound patent for NovoSeven
<SUP>
	&reg;
</SUP>
	has expired
	in all major markets, Novo Nordisk holds two formulation patents on the room temperature stable preparation of NovoSeven
<SUP>
	&reg;
</SUP>
	,
	which provides coverage of this formulation until 2023 and 2024, respectively, in all major markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The expiry of the drug compound patent
	has had limited impact on sales of NovoSeven
<SUP>
	&reg;
</SUP>
	due to the complexity relating to the regulatory pathways for &lsquo;biosimilar&rsquo;
	coagulation factors in the United States, the EU and Japan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The U.S. Health Care Reform includes the
	establishment of a regulatory pathway for approving biosimilar versions of originator proteins. Therefore, in the future, a biosimilar
	version of rFVIIa could be submitted to the FDA as a Biologics License Application (&ldquo;BLA&rdquo;) under 351(k) of the U.S.
	Public Health Service Act and be approved if it fulfills the requirements, i.e. that the product is &lsquo;biosimilar&rsquo; to
	its reference product and that no clinically meaningful differences between the products in terms of safety, purity and potency
	are seen.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the EU, guidelines for the development
	of biosimilar products have been available since late 2005; however, to date these guidelines do not apply to coagulation factors
	because of their complexity. The guideline for biosimilar products in Japan includes requirements similar to those established
	in Europe.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To date, we have only seen approvals of
	competing rFVIIa products in Russia, Kazakhstan, Azerbaijan, Uzbekistan and Iran. New information is regularly being compiled to
	assess whether the clinical programs for these compounds could contribute towards fulfilling regulatory requirements in the United
	States, the EU and Japan. As such, we still believe that the expiry of our compound patent for NovoSeven
<SUP>
	&reg;
</SUP>
	will continue
	to have an insignificant impact in the near term on sales, results of operations and liquidity in the major geographical segments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total sales of Norditropin
<SUP>
	&reg;
</SUP>
	were
	DKK 8,770 million in 2016 (DKK 7,820 million in 2015). Today, Norditropin
<SUP>
	&reg;
</SUP>
	is not covered by a drug compound patent.
	However, the formulation used is covered by a formulation patent that expires in 2017 in the United States, Europe and Japan. Furthermore,
	the pen devices that patients use to inject growth hormone are covered by separate patents. Today, all Novo Nordisk growth hormone
	products are supplied in pen devices. While marketed growth hormone products in the United States are similar in terms of efficacy
	and safety profile and despite the presence of biosimilar growth hormone products on the market, Norditropin
<SUP>
	&reg;
</SUP>
	is
	differentiated by its high level of temperature stability and the FlexPro
<SUP>
	&reg;
</SUP>
	device in which it is offered. In 2016,
	sales of Norditropin
<SUP>
	&reg;
</SUP>
	increased in the United States reflecting a significant positive non-recurring adjustment
	to rebates in the Medicaid patient segment relating to the period 2010-2015. This positive impact has been partly offset by lower
	volumes. The expiry of our compound patent for Norditropin
<SUP>
	&reg;
</SUP>
	is not expected to significantly impact sales, results
	of operations and liquidity in any geographical segments in the near term, but a lower price level for Norditropin
<SUP>
	&reg;
</SUP>
	is expected in the United States in 2017 as a result of formulary negotiations with pharmacy benefits managers and other payers
	concluded in 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total sales of Vagifem
<SUP>
	&reg;
</SUP>
	were DKK 2,995
	million in 2016 (DKK 3,228 million in 2015). The Vagifem
<SUP>
	&reg;
</SUP>
	10 mcg treatment regimen is protected by patent in
	the United States, EU and Japan. In the United States, three generic manufactures have been granted access to the patent ,
	one of them Amneal Pharmaceuticals who launched its authorized generic of Vagifem
<SUP>
	&reg;
</SUP>
	in October 2016. This loss
	of exclusivity has led to a rapid erosion of Vagifem
<SUP>
	&reg;
</SUP>
	sales in the United States during the fourth quarter of
	2016. The erosion is expected to continue in 2017. In the EU and Japan, the patent expires in December 2021. The European
	patent is currently being opposed by two generic manufacturers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Impact of regulation
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As a pharmaceutical company, Novo Nordisk
	depends on government approvals related to production, development, marketing and reimbursement of its products. Important regulatory
	bodies include the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare and the Chinese Food
	and Drug Administration. Treatment guidelines from non-governmental organizations such as the European Association for the Study
	of Diabetes and the American Diabetes Association may also impact the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	Disclosure
	pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
</I>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Pursuant
	to Section 13(r) of the Securities Exchange Act of 1934, Novo Nordisk is obliged to provide disclosure if, during 2016, it or any
	of its affiliates have engaged in certain Iran-related activities or transactions with persons designated under Executive Order
	13224 or Executive Order 13382.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	As
	a global organization, Novo Nordisk conducts business with customers in Iran, including the Government of Iran (the &ldquo;GOI&rdquo;).
	Novo Nordisk&rsquo;s activities in Iran relate primarily to sales of pharmaceutical products and devices within the diabetes and
	obesity care and biopharmaceutical business segments.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Novo
	Nordisk Pars (&ldquo;NN Pars&rdquo;), a wholly-owned affiliate of Novo Nordisk A/S located in Iran, contracts with four companies
	that may be GOI-controlled (Exir, Ferdows Distribution Co., Darou Pakhsh Distribution Co. and Hedjat Distribution Co.) to distribute
	its products. NN Pars also sponsors educational programs and congresses organized by GOI-controlled medical universities, and hosts
	health care professionals employed by these medical universities at similar programs in Iran and other locations. Additionally,
	NN Pars makes donations to GOI-controlled public health organizations focusing on diabetes awareness and policy. NN Pars receives
	payments from, and makes payments to Iranian banks (certain of which are owned by the GOI and/or are designated under Executive
	Order 13224 or Executive Order 13382) relating to the sales of pharmaceutical products and devices.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	In
	addition, in 2016, NN Pars purchased land from Barakat Industrial and Pharmaceutical Company (&ldquo;Barakat&rdquo;), a GOI-controlled
	land holding company, in order to construct a manufacturing facility in Iran. NN Pars will make monthly payments to Barakat for
	the duration of NN Pars&rsquo; ownership of the land, which Barakat will use to facilitate delivery of utility services to the
	site from GOI-owned utility companies. Novo Nordisk expects to invest approximately EUR 70 million over the course of the next
	five years to build the manufacturing facility, which will be used for assembly and packaging of insulin pens for use in Iran.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	The
	German affiliate of NNE Pharmaplan A/S, a wholly-owned subsidiary of Novo Nordisk A/S, contracts with SOHA Helal Iran Medical Devices
	Co., a GOI-controlled company, to provide raw materials and spare parts for production of dialysis and leucocyte filters and syringes.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Novo
	Nordisk&rsquo;s gross revenue related to transactions with GOI-owned or controlled entities in 2016 were not in excess of DKK 850
	million. Novo Nordisk does not allocate its net profit on a country-by-country or activity-by-activity basis, other than as set
	forth in Novo Nordisk&rsquo;s consolidated financial statements prepared in accordance with IFRS as issued by the IASB; however,
	Novo Nordisk estimates that its net profit attributable to the transactions with the GOI discussed above would not exceed a de
	minimis percentage of the Group&rsquo;s total net profit in 2016.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	In
	addition, Novo Nordisk conducts business with customers in Syria and Sudan. These activities relate to sales of pharmaceutical
	products and devices within the diabetes and biopharmaceutical business segments. Gross revenue related to transactions in 2016
	was not in excess of DKK 30 million in any of the two countries. Novo Nordisk estimates that their net profits attributable to
	the transactions with Syria and Sudan would represent an even smaller de minimis percentage of the Group&rsquo;s total net profit
	in 2016.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	The
	purpose of Novo Nordisk&rsquo;s Iran, Syria and Sudan-related activities is to provide access to important and life-saving pharmaceutical
	products such as insulin and haemophilia products to patients in these countries, and to improve the healthcare of the Iranian,
	Syrian and Sudanese people in accordance with a key component of Novo Nordisk&rsquo;s access to care strategy. For that purpose,
	Novo Nordisk intends to continue these activities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Organizational structure
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For information regarding the organizational
	structure and securities exchange listings of Novo Nordisk A/S, the parent company Novo A/S and the Novo Nordisk Foundation and
	the ownership structure, reference is made to the sections &lsquo;Corporate governance&rsquo; on pages 46-49 and &lsquo;Shares
	and capital structure&rsquo; on pages 44-45 in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Companies in the Novo Nordisk Group are
	listed in the Company&rsquo;s
<I>
	Annual Report 2016
</I>
	on page 95, &lsquo;Companies in the Novo Nordisk Group.&rsquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Property, plant and equipment
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company has its headquarters in Bagsv&aelig;rd,
	Denmark, where it occupies a number of buildings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company believes that its current production
	facilities, including facilities under construction and planned for construction, are sufficient to meet its capacity requirements,
	including the capacity for meeting growing demand in the future for the products NovoLog
<SUP>
	&reg;
</SUP>
	/ NovoRapid
<SUP>
	&reg;
</SUP>
	,
	NovoLog Mix
<SUP>
	&reg;
</SUP>
	/ NovoMix
<SUP>
	&reg;
</SUP>
	, Levemir
<SUP>
	&reg;
</SUP>
	, Victoza
<SUP>
	&reg;
</SUP>
	, Tresiba
<SUP>
	&reg;
</SUP>
	,
	Ryzodeg
<SUP>
	&reg;
</SUP>
	, Xultophy
<SUP>
	&reg;
</SUP>
	, Saxenda
<SUP>
	&reg;
</SUP>
	, NovoEight
<SUP>
	&reg;
</SUP>
	, Norditropin
<SUP>
	&reg;
</SUP>
	and devices. Reference is made to the sections &lsquo;Capital expenditures in 2016, 2015 and 2014&rsquo; under Item 4 for more
	information about the current expansion programs. For the nature of the Company&rsquo;s property, plant and equipment, as of December
	31, 2016 and 2015, reference is made to Note 3.2 &lsquo;Property, plant and equipment&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4 INFORMATION ON THE COMPANY
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The major production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United
	States, France, China and Brazil. There are no material encumbrances on the properties; however, the facilities in Tianjin, China
	are constructed on land where the remaining term of the lease is 30 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Active pharmaceutical ingredient (API)
	production is located in Denmark, primarily in Kalundborg and with secondary locations in Hiller&oslash;d, Bagsv&aelig;rd and Gentofte
	although two API production sites in the United States are being established.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table sets forth certain
	information regarding our major production sites.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE">
	Major production
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE">
	facilities
</P>
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD; TEXT-INDENT: 14.15PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Size of
<BR>
	production area
<BR>
	(square meters)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Major Production Activities
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 10PT">
	Kalundborg, Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD; WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	176,000
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 42%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Active pharmaceutical ingredients for diabetes and obesity
	as well as products for diabetes
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.7PT; TEXT-INDENT: -17.85PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.7PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -17.85PT">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Active pharmaceutical ingredients for haemophilia.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Products for biopharmaceuticals
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Bagsv&aelig;rd, Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	118,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P>
<FONT STYLE="FONT-SIZE: 10PT">
	Products
	for diabetes and obesity
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Hiller&oslash;d, Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	105,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Durable
	devices and components for disposable devices
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Products for diabetes and obesity
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Active pharmaceutical ingredients for haemophilia
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tianjin, China
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	68,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Products
	for diabetes
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Production of durable devices
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Gentofte, Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	68,500
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Active
	pharmaceutical ingredients for glucagon and growth hormone therapy
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Products for growth hormone therapy, glucagon and haemophilia
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Montes Claros, Brazil
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	58,700
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Products
	for diabetes
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Gel production for active pharmaceutical ingredients
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chartres, France
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	49,900
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P>
	Products
	for diabetes
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	M&aring;l&oslash;v, Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	47,000
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P>
	Products
	for hormone replacement therapy
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Products for oral antidiabetes treatment
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Clayton, North Carolina,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	United States
</P>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	34,200
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Products
	for diabetes and obesity
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the active production sites
	listed above, Novo Nordisk acquired a production plant in New Hampshire, United States in August 2014. The new facility will increase
	production capacity of active pharmaceutical ingredients for the portfolio of biopharmaceuticals, and is expected to be operational
	in 2018. The production area of the facility is 14,800 square meters. The expected amount of investments for this new facility
	is approximately DKK 800 million. The facility is financed by cash flow from operating activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In May 2015, Novo Nordisk initiated the
	construction of a new facility in Kalundborg, Denmark for producing API for NovoSeven
<SUP>
	&reg;
</SUP>
	and future products for treating
	haemophilia. The facility is expected to be operational by the end of 2020. The production area of the facility is 7,500 square
	meters. The expected amount of expenditures for this facility is approximately DKK 1,500 million. The facility is financed by cash
	flow from operating activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_COMPANY_INFORMATION>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 4A&#9;Unresolved staff comments
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November 2015, Novo Nordisk initiated
	the construction of a new facility in Hiller&oslash;d, Denmark for producing medicines for the treatment of diabetes and obesity.
	The facility is expected to be ready for use in 2019. The production area of the facility is 10,300 square meters. The expected
	amount of expenditures for this facility is approximately DKK 2,100 million. The facility is financed by cash flow from operating
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2016, Novo Nordisk initiated the
	construction of a new diabetes API production facility in Clayton, North Carolina, United States. The facility is expected to be
	ready for use in 2020. The expected amount of expenditures for this facility is approximately DKK 13,200 million. The facility
	will be financed by cash flow from operating activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_007">
</A>
	ITEM
</FONT>
<FONT STYLE="FONT-SIZE: 12PT">
	4A
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT; TEXT-TRANSFORM: NONE">
	UNRESOLVED
	STAFF COMMENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="FIS_OPERATING_AND_FINANCIAL_REVIEW"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_008">
</A>
	ITEM 5
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	OPERATING
	AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 58.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -58.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	Critical
	accounting estimates
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 1.1 &lsquo;Principal
	accounting policies and key accounting estimates&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	New
	accounting pronouncements
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 1.2 &lsquo;Changes
	in accounting policies and disclosures&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	OPERATING RESULTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to the section &lsquo;Forward-looking
	statements&rsquo; contained on page 2 and the discussion under the caption &lsquo;Risk factors&rsquo; contained under Item 3. Reference
	is further made to our
<I>
	Annual Report 2016
</I>
	&lsquo;Risk management&rsquo; on pages 40-43.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The financial condition of the Group and
	its development are described in our
<I>
	Annual Report 2016
</I>
	and our
<I>
	Annual Report 2015
</I>
	. The information in this section
	is based on these reports and should be read in conjunction with the annual reports. The analysis and discussions included in the
	annual reports are primarily based on the consolidated financial statements which are prepared in accordance with International
	Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and endorsed by the European
	Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	2016 compared with 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following portions of our
<I>
	Annual
	Report 2016
</I>
	constitute the Board of Directors&rsquo; and Executive Management&rsquo;s discussion and analysis of results of
	operations (incorporated herein by reference):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&lsquo;Accomplishments
	and results 2016&rsquo; (pages 1-15)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	2015 compared with 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following portions of our
<I>
	Annual
	Report 2015
</I>
	constitute the Board of Directors&rsquo; and Executive Management&rsquo;s discussion and analysis of results of
	operations (incorporated herein by reference):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&lsquo;Accomplishments
	and results 2015&rsquo; (pages 1-15)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 5&#9;OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Segment information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 2.2 &lsquo;Segment
	information&rsquo; in our
<I>
	Annual Report 2016
</I>
	for details on segmented results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Inflation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Inflation for the three most recent fiscal
	years has not had a material impact on the Group&rsquo;s Net sales or Net profit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Foreign currencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The majority of Novo Nordisk&rsquo;s sales
	are in foreign currencies, mainly USD, EUR, CNY, JPY, GBP and CAD, while a significant proportion of production, research and development
	costs are carried in DKK. Consequently, Novo Nordisk has significant exposure to foreign exchange risks and engages in significant
	hedging activities where the most significant exposure and hedging are related to USD, CNY, JPY, GBP and CAD, while the EUR exchange
	rate risk is regarded as low due to the Danish fixed-rate policy towards EUR. Thus, Novo Nordisk does not hedge the EUR exchange
	rate risk. For further description of foreign currency exposure, reference is made to the disclosure in Note 4.2 &lsquo; Financial
	risks&rsquo; in our
<I>
	Annual Report 2016
</I>
	and for further description of foreign currency exposure and hedging activities,
	reference is made to the description of financial instruments in Note 4.3 &lsquo;Derivative financial instruments&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Governmental policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to pages 16-43 &lsquo;Our
	business&rsquo; in our
<I>
	Annual Report 2016
</I>
	and Item 4.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Liquidity and Capital Resources
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #002060">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk maintains a centralized approach
	to the management of the Group&rsquo;s financial risks. The overall objectives and policies for Novo Nordisk&rsquo;s financial
	risk management are outlined in the Novo Nordisk Treasury Policy, which is approved by the Board of Directors. The Treasury Policy
	governs the Group&rsquo;s use of financial instruments. For further information, reference is made to Item 11.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Financial resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to page 59 &lsquo;Balance
	sheet&rsquo; and page 60 &lsquo;Statement of cash flows for the year ended 31 December&rsquo; in our
<I>
	Annual Report 2016.
</I>
	In
	addition Novo Nordisk has obtained a credit rating from two independent external rating agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk believes its financial resources are sufficient to meet its requirements for at least the next 12 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Cash flow in 2016, 2015
	and 2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to page 60 &rsquo;Statement
	of cash flows for the year ended 31 December&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The most significant source of cash flow
	from operating activities is sales of diabetes and obesity care and biopharmaceutical products. Generally, other factors that affect
	operating earnings, such as pricing, volume, costs and exchange rates, also have an impact on realized cash flow from operating
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no material restrictions on the
	ability of subsidiaries with material cash amounts to transfer funds to the Parent Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Trade receivable program
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Trade receivable program, as of December
	31, 2016, 2015 and 2014, respectively, are shown in Note 4.2 &lsquo;Financial risks&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 5&#9;OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Debt financing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	No long-term loans were outstanding as
	of December 31, 2016 or 2015. Reference is made to page 57 &lsquo;Balance sheet and Note 4.7 &lsquo;Financial assets and liabilities&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	for information on Current debt.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Financial instruments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk only hedges commercial exposures
	and consequently does not enter into derivative transactions for trading or speculative purposes. Currency hedging is done with
	foreign exchange forwards and foreign exchange options. Reference is made to Note 4.2 &lsquo;Financial risks&rsquo; and Note 4.3
	&lsquo;Derivative financial instruments&rsquo; in our
<I>
	Annual Report 2016
</I>
	for further information on financial instruments
	including currency exposure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<B>
	Commitments for capital expenditure etc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Contractual obligations for capital expenditure
	and other contingent liabilities as of December 31, 2016 and 2015, respectively, are shown in Note 5.3 &lsquo;Commitments&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Executive Management of the Group believes
	that the obligations are covered by the Group&rsquo;s financial resources as well as expected future cash flows from operating
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Research and development, patents and licenses, etc.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #002060">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s research activities
	utilize biotechnological methods based on genetic engineering, advanced protein chemistry and protein engineering. These methods
	have played a key role in the development of the production technology which is used in the manufacturing of insulin, GLP-1, recombinant
	blood clotting factors, human growth hormone and glucagon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The focus of Novo Nordisk&rsquo;s research
	and development is on therapeutic proteins within diabetes, obesity, haemophilia and growth disorders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to note 2.3 &lsquo;Research
	and development costs&rsquo; in our
<I>
	Annual Report 2016
</I>
	for Research and development costs in 2016, 2015 and 2014, respectively.
	Novo Nordisk&rsquo;s research and development organization comprised approximately 6,000 employees as of December 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In general, we expect that growth in research
	and development spending will follow a trend in line with sales growth indicating that the research and development cost to sales
	ratio is expected to be relatively constant in the foreseeable future. Thus, we expect to continue an expenditure level of around
	12-14% of sales in research and development activities going forward.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The development projects that accounted
	for the highest research and development spend in 2016 were related to the initiation of the 3a program, PIONEER, for oral semaglutide
	(OG217SC) which started recruiting in Q1 2016 as well as Tresiba
<SUP>
	&reg;
</SUP>
	related to the finalisation of the cardiovascular
	outcome trial for DEVOTE, and the SWITCH trials. Further, research and development spend was driven by the finalisation of the
	phase 3a program, SUSTAIN, for injectable semaglutide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Information related to the spend
	ratio on clinical development activities and research activities can be found in Note 2.3 &lsquo;Research and development costs&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Information related to selected
	research and development projects can be found under &lsquo;Pipeline overview&rsquo; on pages 20-21 in our
<I>
	Annual Report 2016.
</I>
	Furthermore, a broader overview of our business activities can be found on pages 16-43 &lsquo;Our business&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 14.2PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 5&#9;OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following Novo Nordisk compounds are currently in phase
	3 development or have recently been filed for regulatory approval:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 31%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-TRANSFORM: UPPERCASE; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Compound / brand name / indication
</FONT>
</TD>
<TD STYLE="WIDTH: 51%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Year entered into phase 3 or filed with the regulatory authorities
</FONT>
</TD>
<TD STYLE="WIDTH: 18%; BORDER-TOP: BLACK 2.25PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Patent expiration
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Semaglutide (NN9535) / Type 2 diabetes
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.1PT">
	Phase 3 completed in 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	United States: Filed for regulatory review December
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.1PT">
	EU: Filed for regulatory review December 2016.
</P>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2031
<SUP>
	1
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Fast-acting insulin aspart (NN1218) / Type 1 &amp; 2 diabetes
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	Phase 3 completed in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	United States: Filed for regulatory review December,
	2015. Complete Response Letter received October 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.1PT">
	EU: Approved in January 2017.
</P>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2030
<SUP>
	2
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Oral semaglutide (NN9924) / Type 2 diabetes
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 7.1PT">
	Phase 3 initiated in 2016.
</P>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2031
<SUP>
	1&#9;
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	N9-GP (NN7999) / Haemophilia B
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	Phase 3 completed in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	United States: Filed for regulatory review May
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	EU: Filed for regulatory review January 2016.
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	2027
<SUP>
	1
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	N8-GP (NN7088) / Haemophilia A
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	Phase 3 completed in 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	Filing for regulatory review in the United States
	and EU expected around 2018.
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	2032
<SUP>
	3
</SUP>
</FONT>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	NN8640 Once-weekly human growth hormone / Growth disorder
</P>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 7.1PT">
	Phase 3 in AGHD started in 2014.
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	2034
<SUP>
	4
</SUP>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
<SUP>
	1
</SUP>
	Current estimate
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
<SUP>
	2
</SUP>
	Formulation patent (compound patent has expired)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
<SUP>
	3
</SUP>
	Current estimate United States. EU estimate 2034, Japan expiry 2034
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
<SUP>
	4
</SUP>
	Current estimate United States. EU estimate 2035, Japan expiry 2035
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	During 2016 Novo Nordisk has
	not discontinued any development projects in phase 3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	In determining whether or not
	any project or group of related projects is significant, we consider the following qualitative and quantitative criteria:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 14.2PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Assessment of the
	unmet medical need targeted with the specific project;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The inherent project
	risk including the risk of safety issues, unsatisfactory tolerability profile, limitations on the efficacy of the compound;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Timeline for completing
	the clinical testing and submitting an application for approval to regulatory authorities;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regulatory authorities&rsquo;
	position towards approval and drug label;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Changes in competitive
	landscape during the development and approval cycle including competing drugs being developed by others;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Changes in medical
	practice during the development period;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Position of payers,
	the medical society and patients towards treatment with drug and price of drug;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected uptake
	in market following launch; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 32.2PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 0.55PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected net present
	value of the project.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	In assessing the criteria listed
	above, and as described in &lsquo;Risk management&rsquo; on pages 40-43 in our
<I>
	Annual Report 2016
</I>
	, it is important to note
	that at any one stage of development, due to the uncertainties inherent to clinical development and the regulatory approval process,
	there is a significant degree of uncertainty and risk that the project will not be successful. The nature of our development activities
	is such that a compound must first be proven to work by means of multiple clinical trials, which may require treatment of thousands
	of patients and could take years to complete. Even if initial results of preclinical studies or clinical trial results are promising,
	we may obtain different results that fail to show the desired levels of safety and efficacy, or we may not obtain applicable regulatory
	approval for a variety of other reasons. The compound must be accepted by either the FDA, the European Medicines Agency or similar
	agencies around the world, each of which may have differing requirements. During each stage, there is a substantial risk that we
	will encounter serious obstacles which will further delay us, or that we will not achieve our goals and, accordingly, may abandon
	a product in which we have invested substantial resources. Furthermore, the commercial potential of a project is dependent on the
	label granted by the regulatory authority upon approval. The label specifies for which indications a product can be used, major
	and minor safety concerns associated with drug treatment as well as if the drug can be combined with other types of medication.
	Thus a label can restrict usage substantially.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 5&#9;OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Due to the risks and uncertainties
	involved in progressing through pre-clinical development and clinical trials, and the time and cost involved in obtaining regulatory
	approvals, we cannot reasonably estimate the nature, timing, completion dates and costs of the efforts necessary to complete the
	development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.55PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Given the uncertainties related
	to the process of product development, during the periods presented in our 2016 Form 20-F no single project in product development
	was significant based on the qualitative and quantitative criteria. However, during the periods presented two groups of projects
	were considered significant; the diabetes and obesity care group and biopharmaceuticals group.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 17.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to the caption &lsquo;Risk
	factors&rsquo; contained under Item 3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; COLOR: #001965">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	D.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	TREND INFORMATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The key drivers behind Novo Nordisk&rsquo;s
	performance continue to be the changes in demographics globally reflecting a continuous growth in the proportion of people who
	live in cities (urbanization), an increasing proportion of elderly people and a growing problem of obesity. These trends have contributed
	to the significant increase in the number of people with diabetes worldwide. According to the International Diabetes Federation,
	the number of people with diabetes is expected to increase to around 642 million by 2040 from 415 million in 2015. Diabetes and
	obesity care is Novo Nordisk&rsquo;s largest segment comprising approximately 80% of sales. The epidemic growth in the number of
	people with diabetes, continuing transition from older to newer insulin generations, and new delivery devices and market share
	gains in some segments of the market are all driving Novo Nordisk&rsquo;s growth within the diabetes and obesity care segment.
	Further, the roll-out of a number of new products within diabetes and obesity care (Tresiba
<SUP>
	&reg;
</SUP>
	, Ryzodeg
<SUP>
	&reg;
</SUP>
	,
	Xultophy
<SUP>
	&reg;
</SUP>
	, FIAsp
<SUP>
	&reg;
</SUP>
	and Saxenda
<SUP>
	&reg;
</SUP>
	) are expected drivers of sales in the segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The other segment of Novo Nordisk is biopharmaceuticals,
	which comprises haemophilia care, growth hormone therapy and hormone replacement therapy. In 2016, sales of haemophilia care products
	was unchanged measured in local currencies and declined slightly when measured in Danish kroner, driven by lower Novoseven
<SUP>
	&reg;
</SUP>
	sales, partially offset by the continued roll-out of NovoEight
<SUP>
	&reg;
</SUP>
	in the United States, Europe and Japan. With new
	competitive products likely to enter the market for treatment of haemophilia with inhibitors in 2017/18, Novoseven
<SUP>
	&reg;
</SUP>
	sales are likely to be at risk of further erosion in subsequent years. The growth hormone therapy franchise benefited from increasing
	sales of the liquid formulation Norditropin
<SUP>
	&reg;
</SUP>
	, delivered in ready-to-use prefilled devices. The sales growth in 2016
	of Norditropin
<SUP>
	&reg;
</SUP>
	was positively impacted by approximately 8 percentage points due to non-recurring adjustments to
	rebates in the Medicaid patient segment in the United States. Sales of the hormone replacement therapy product Vagifem
<SUP>
	&reg;
</SUP>
	declined in 2016 due to the loss of exclusivity for the sale of Vagifem
<SUP>
	&reg;
</SUP>
	in the United States since October
	1, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_LIQUIDITY_CAPITAL>
</EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 6&#9;DIRECTORS, EXECUTIVE MANAGEMENT AND EMPLOYEES
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the United States, significant sales
	rebates are paid in connection with public healthcare insurance programs, such as Medicare and Medicaid, as well as rebates to
	pharmacy benefit managers (PBMs) and managed healthcare plans. Key customers in the United States include private payers, PBMs
	and government payers. Increasingly, PBMs and health plans play a key role in negotiating price concessions with drug manufacturers
	on behalf of private payers for both the commercial and government channels, and determining the list of drugs covered in the health
	plan&rsquo;s formulary. Specifically, there are two primary drivers:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Payer pressure to reduce the overall drug
	costs has resulted in greater focus on negotiating higher rebates from drug manufacturers. Private payers are increasingly keen
	to adopt narrow formularies that exclude certain drugs, while securing increased rebates from the preferred brand.
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Recent industry consolidation among payers
	has led to increasing pricing pressure for pharmaceutical companies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2016, payers have continued to leverage
	their size and control to demand higher rebates. Moreover, actions by companies in the diabetes care market to increase list prices
	have been limited and the introduction of new products by competitors has further increased the downward pressure on prices. As
	a result, the development in average prices after rebates for the Novo Nordisk portfolio in 2016 in the United States has been
	flat to slightly declining.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For 2017, the average prices for the Novo
	Nordisk portfolio in the United States after rebates are expected to be moderately lower compared with the levels in 2016, due
	to the challenging pricing environment, especially in the basal insulin segment following the launch of a biosimilar glargine in
	December 2016 but also in the human growth hormone segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For further information on trends, reference
	is made to the section &lsquo;Accomplishments and results 2016&rsquo; on pages 1-15 in our
<I>
	Annual Report 2016
</I>
	. Information
	about expectations for the financial year 2017 can be found on page 8 in the subsection &lsquo;Outlook 2017.&rsquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; COLOR: #001965">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	E.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	OFF-BALANCE SHEET ARRANGEMENTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 4.2 &lsquo;Financial
	risks&rsquo; and Note 5.3 &lsquo;Commitments&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; COLOR: #001965">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	F.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 5.3 &lsquo;Commitments&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_009">
</A>
	ITEM 6
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	DIRECTORS,
	EXECUTIVE MANAGEMENT AND EMPLOYEES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Directors and EXECUTIVE Management
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Reference
	is made to pages 54-55 in our
<I>
	Annual Report 2016
</I>
	for name, position and period of service as director for the members of
	the Board of Directors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to page 56 in our
<I>
	Annual
	Report 2016
</I>
	for name, position, age, year of appointment and year of joining Novo Nordisk for the members of Executive Management.
	On January 1, 2017, Lars Fruergaard J&oslash;rgensen replaced Lars Rebien S&oslash;rensen as president and CEO. Furthermore, effective
	September 1, 2016, Jerzy Gruhn and Jesper H&oslash;iland stepped down from the Executive Management of Novo Nordisk.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors has the overall
	responsibility for the affairs of the Company. Reference is made to pages 46-49 in our
<I>
	Annual Report 2016.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 6&#9;DIRECTORS, EXECUTIVE MANAGEMENT AND EMPLOYEES
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The activities of the members of Board of Directors and members
	of Executive Management outside the Company are included in our
<I>
	Annual Report 2016
</I>
	on pages 54-56.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no family relationships between
	the Board of Directors, Executive Management or between any of the members of the Board of Directors and any member of Executive
	Management. No director or member of Executive Management has been elected according to an arrangement or understanding with shareholders,
	customers, suppliers or others. As required by the Danish Companies Act, directors are elected at General Meetings by simple majority
	vote. In addition, four employee representatives are elected for four-year terms by the employees of Novo Nordisk A/S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Compensation
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to the section &lsquo;Remuneration&rsquo;
	on page 50-53 and Notes 5.1 and 5.2 in our
<I>
	Annual Report 2016
</I>
	regarding compensation.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Board practices
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #002060">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to &lsquo;Corporate governance&rsquo;
	on pages 46-49 in our
<I>
	Annual Report 2016
</I>
	regarding board practices. The year of election for each member of the Board of
	Directors and the year of appointment for each member of Executive Management is included in our
<I>
	Annual Report 2016
</I>
	on pages
	54-56.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Employees
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to the section entitled
	&lsquo;Employees&rsquo; on pages 11-12 and &lsquo;Performance highlights&rsquo; on page 15 in our
<I>
	Annual Report 2016
</I>
	regarding
	the total number of full-time employees in Novo Nordisk at year-end for the years 2012&ndash;2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In November 2016, Novo Nordisk reduced
	its global workforce by approximately 2%. The decision was one of several actions taken to reduce operating costs in the face of
	a challenging competitive environment, especially in the United States. The workforce reductions affected R&amp;D units, headquarter
	staff functions and positions in the global commercial organization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 2PT SOLID">
	Employees
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 2PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-TOP: BLACK 2PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Employees outside Denmark as a percentage of total number of employees
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	57
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	58
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Executive Management believes that the
	Company has a good relationship with its employees in general and with the labor unions of the Novo Nordisk employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk believes that the current
	personnel policy results in low staff turnover, high engagement, and ease in recruiting new employees. The Company has not experienced
	any significant labor disputes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	E.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Share ownership
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For information on the Board of Directors&rsquo;
	and Executive Management&rsquo;s individual holdings of shares and restricted stock units and granting of shares, reference is
	made to the section &lsquo;Remuneration&rsquo; on pages 50-53 and Note 5.2 &lsquo;Management&rsquo;s holdings of Novo Nordisk shares&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	. The members of the Board of Directors and Executive Management and key management executives
	in the aggregate hold less than 1% of the beneficial ownership of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_DIRECTORS_AND_OFFICERS>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 7&#9;MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For information on the Board of Directors&rsquo;
	and Executive Management&rsquo;s individual holdings of and trading in Novo Nordisk shares during 2016, reference is made to the
	section &lsquo;Remuneration&rsquo; on pages 50-53 and Note 5.2 &lsquo;Management&rsquo;s holding of Novo Nordisk shares&rsquo;
	in our
<I>
	Annual Report 2016
</I>
	. As of February 1, 2017 the Board of Directors and Executive Management owned 854,843 B shares
	excluding the holding of Novo Nordisk shares of former CEO Lars Rebien S&oslash;rensen.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the period from January 1, 2017 until
	February 2, 2017, no B shares were sold or purchased by the members of the Board of Directors or Executive Management. The internal
	rules on trading in Novo Nordisk securities by members of the Board of Directors and Executive Management only permit trading in
	the 15 calendar-day period following each quarterly earnings announcement. Following the quarterly earnings announcement release
	on February 2, 2017, the Executive Management received 57,551 B shares in accordance with the long-term incentive program and a
	total of 34,492 B shares were sold, hence as of February 2, 2017, the Board of Directors and Executive Management owned 946,886
	B shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To commemorate that the turnover of the
	group passed DKK 100 billion for the first time in 2015 all employees in the Company (excluding NNE A/S and Steno Diabetes Center
	A/S) as per January 1, 2016 were offered 50 restricted stock units. A restricted stock unit gives the holder the right to receive
	one Novo Nordisk B- share free of charge in February 2019 subject to continued employment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	It is estimated that 1,500,000 B shares
	will be needed for the program. No dividends will be paid on the restricted stock units and the holders will have no voting rights
	until the restricted stock units are converted to shares in February 2019.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 5.1 &lsquo;Share
	based payment schemes&rsquo; in our
<I>
	Annual Report 2016.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_010">
</A>
	ITEM 7
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	MAJOR
	SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #001965">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Major Shareholders
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The total share capital of the Company
	is split in two classes, A shares and B shares, each with different voting rights. The A shares have 200 votes per DKK 0.20 of
	the A share capital and the B shares have 20 votes per DKK 0.20 of the B share capital. Treasury shares have no votes at the Annual
	General Meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All of the A shares of the Company are
	held by Novo A/S, a wholly-owned subsidiary of the Novo Nordisk Foundation (the &lsquo;Foundation&rsquo;). As of December 31,
	2016, the A shares represented approximately 73% of the votes exercisable at the Annual General Meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Foundation is a self-governing and
	self-owned organization whose main purposes are to be a stable base for the business and research activities of the subsidiaries
	of Novo A/S, and to support medical research and other scientific, humanitarian and social objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The purpose of Novo A/S in relation to
	Novo Nordisk A/S is to administer its portfolio of securities and minority capital interests and to administer and vote on the
	A shares and B shares in Novo Nordisk A/S, thereby creating a satisfactory financial return for the Foundation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under its statutes, the Foundation is
	governed by a Board of Governors, which must be comprised of at least six and not more than 12 members and at least two members
	must have a medical or scientific background. Members of the Foundation&rsquo;s Board of Governors are typically nominated by
	the chairman and elected by a two-thirds vote of the members who have themselves been elected pursuant to the statutes. Any member
	can be removed as provided for in the Danish Act on Foundations (&lsquo;lov om erhvervsdrivende fonde&rsquo;). In addition, employee
	representatives are elected for four-year terms by the employees of the subsidiaries of the Foundation, in accordance with Danish
	law. No person or entity exercises any kind of formal influence over the Foundation&rsquo;s Board. The Foundation&rsquo;s Board
	currently consists of nine persons, one of whom is also an employee elected member of the Board of Directors of Novo Nordisk A/S
	(Anne Marie Kverneland).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 7&#9;MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under its statutes, Novo A/S is governed
	by a Board of Directors, which must be comprised of at least three and not more than six members who are elected annually by shareholder
	vote. According to the Foundation&rsquo;s statutes, its Board of Directors can and shall provide for members of its own Board
	of Directors to be elected to Novo A/S&rsquo;s Board of Directors. Novo A/S&rsquo;s Board of Directors currently has five members,
	with two directors who are also members of the Board of the Foundation (Sten Scheibye and Steen Risgaard) and two directors who
	are also members of the Board of Directors of Novo Nordisk A/S (G&ouml;ran Ando and Jeppe Christiansen). The Chairman of the Foundation&rsquo;s
	Board of Governors (Sten Scheibye) serves as the Chairman of Novo A/S&rsquo;s Board of Directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	According to the statutes, the Foundation,
	in exercising its voting rights through Novo A/S at Novo Nordisk A/S&rsquo;s General Meetings, must vote with regard for what is
	in Novo Nordisk&rsquo;s best interest. A shares held by Novo A/S cannot be sold or be subject to any disposition so long as the
	Foundation exists. The dissolution of the Foundation or any change in its objectives requires the unanimous vote of the Foundation&rsquo;s
	Board of Governors. Other changes in the Foundation&rsquo;s statutes require the approval of two-thirds of the members of the Foundation&rsquo;s
	Board of Governors. In addition, changes in the Foundation&rsquo;s statutes require approval of the Danish Foundation Authorities.
	According to its statutes, the Foundation is required to maintain material influence over Novo Nordisk A/S and its majority vote
	in Novo A/S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For further information reference is made
	to &lsquo;Shares and capital structure&rsquo; on pages 44-45 in our
<I>
	Annual Report 2016
</I>
	and to &lsquo;Shares and capital
	structure&rsquo; on pages 44-45 in our
<I>
	Annual Report 2015
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The B shares of the Company are registered
	with V&aelig;rdipapircentralen (&lsquo;VP Securities&rsquo;) and are not represented by certificates. Generally, VP Securities
	does not provide the Company with information with respect to registration. However, set forth below is information as of February
	1, 2017 with respect to (a) any shareholder who is known to the Company to be the owner of more than 5% of any class of the Company&rsquo;s
	securities and (b) the total amount of any class owned by Novo Nordisk A/S and its affiliates (treasury shares) and by the directors
	and Executive Management as a group:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 20%; FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Title of class
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Identity of person or group
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Shares owned
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Percent of class
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Percent of total votes
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	A shares
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Novo A/S
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	537,600,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	B shares
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Novo A/S
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	163,814,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: MIDDLE">
	B shares
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: MIDDLE">
	Novo Nordisk A/S and subsidiaries (treasury shares)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	51,694,676
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	2.57
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	B shares
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Board of Directors and Executive Management
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	854,843
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	**
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	*) The number
	of A shares is calculated as an equivalent of the trading size (DKK 0.20) of the listed B shares but is not formally divided into
	number of shares. The A shares are not listed on any stock exchange.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	**) As of
	February 2, 2017 the shares owned by Board of Directors and Executive Management was 946,886 (corresponding to 0.05 percent of
	class and 0.01 percent of total votes).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2014 and 2015, shares with an aggregate
	purchase price of DKK 14.7 billion and DKK 17.2 billion, respectively, were repurchased under the Company&rsquo;s share repurchase
	program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 7&#9;MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2016, Novo Nordisk announced
	a new DKK 14 billion share repurchase program which was increased by DKK 1 billion to DKK 15 billion in October 2016. Under this
	program and the previous share repurchase program completed in January 2016, 47,900,571 shares corresponding to DKK 15.1 billion
	were repurchased during 2016. The share repurchase program was completed in January 2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 2017, Novo Nordisk announced
	a new DKK 16 billion share repurchase program to be executed during the following 12 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	After the shareholders&rsquo; approval
	of the proposed reduction of the Company&rsquo;s share capital at the Annual General Meeting on March 18, 2016, 50,000,000 shares
	were canceled in April 2016, reducing the number of treasury shares accordingly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As the B shares are in bearer form, it
	is not possible to give an accurate breakdown of the holdings and number of shareholders per country. It is, however, estimated
	that approximately 27% of the B share capital was held in Denmark as of December 31, 2016. Approximately 36% of the B share capital
	is estimated to be held in North America. The estimated total number of shareholders is more than 250,000 of whom more than 200,000
	are estimated to be Danish residents and more than 30,000 to be resident in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Related Party Transactions
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Related parties include the Novo Nordisk
	Foundation, Novo A/S, Novozymes A/S, Xellia Pharmaceuticals ApS (due to shared controlling shareholder, Novo A/S) and NNIT A/S
	being an associated company with shared controlled shareholding between Novo A/S and Novo Nordisk A/S. Novo Nordisk has access
	to certain assets of and can purchase certain services from Novo A/S and Novozymes A/S and vice versa. All agreements relating
	to such assets and services are based on the list prices used for sales to third parties where such list prices exist, or the price
	has been set at what is regarded as market price. The material terms of these agreements are renegotiated on a regular basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Related party transactions in 2016, 2015
	and 2014 were primarily payments for services provided between the Novo Nordisk Group and the Novozymes Group, Xellia Pharmaceuticals
	ApS and transactions with associated companies. The overall financial impact of these related party transactions is limited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As a result of the initial public offering
	of NNIT A/S in March 2015, Novo Nordisk A/S disposed 74.5% out of the 100% interest held in NNIT A/S. Consequently, NNIT A/S is
	an associated company. Being an associated company to Novo Nordisk A/S, NNIT A/S is considered to be a related party. For further
	information reference is made to Note 2.5 &lsquo;Other operating income, net&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since December 31, 2016, there have been
	no significant transactions with related parties out of the ordinary course of business. For further information reference is
	made to Note 5.4 &lsquo;Related party transactions&rsquo; in our
<I>
	Annual Report 2016
</I>
	and Note 5.4 &lsquo;Related party transactions&rsquo;
	in our
<I>
	Annual Report 2015
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There have not been and there are no loans
	to members of the Board of Directors or Executive Management in 2016, 2015 or 2014.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Interests of experts and counsel
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_SECURITY_OWNERS>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 8&#9;FINANCIAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_011">
</A>
	ITEM 8
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	FINANCIAL
	INFORMATION
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Consolidated Statements and Other Financial Information
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #001965">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The financial statements required by this
	item accompany this annual report in the form of our
<I>
	Annual Report 2016
</I>
	(see Exhibit no. 15.1).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Legal proceedings
</B>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Reference
	is made to Note 3.6 &lsquo;Provisions and contingent liabilities&rsquo; in the
</FONT>
	Annual Report 2016
<FONT STYLE="FONT-STYLE: NORMAL">
	regarding
	legal proceedings. After the date of the&nbsp;Annual Report 2016, the class action lawsuit that was filed against Novo Nordisk,
	Eli Lilly and Sanofi in the United States District Court for the District of Massachusetts on January 30, 2017 was voluntarily
	dismissed and re-filed on February 2, 2017 in the United States District Court for the District of New Jersey.
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Dividends
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At the Annual General Meeting in March
	2015, the Board was granted an authorization to distribute extraordinary dividends. Hence the Board of Directors has been given
	authority to pay interim dividends without obtaining specific approval from the Annual General Meeting. In August 2016 Novo Nordisk
	introduced the first interim dividend of DKK 3.00 per share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At the Annual General Meeting March 23,
	2017, the Board of Directors will propose a final dividend of DKK 4.60 for each Novo Nordisk A and B share. The total dividend
	for 2016 of DKK 7.60 includes both the interim dividend of DKK 3.00 for each Novo Nordisk A and B share which was paid in August
	2016, and the final dividend of DKK 4.60 for each Novo Nordisk A and B share to be paid in March 2017. The total dividend increased
	by 19% compared with the 2015 dividend of DKK 6.40 for each Novo Nordisk A and B share. The total dividend for 2016 corresponds
	to a payout ratio of 50.2%, whereas Novo Nordisk&rsquo;s peer group of comparable pharmaceutical companies operated with a payout
	ratio of around 56% in 2015. No dividends will be paid on the Company&rsquo;s holding of its treasury shares. For further information
	reference is made to &lsquo;Shares and capital structure&rsquo;, on pages 44-45 in our
<I>
	Annual Report 2016.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Significant changes
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	No significant events have occurred since the date of the annual
	financial statements. For description of important events and achievements in 2016, reference is made to &lsquo;Accomplishments
	and results 2016&rsquo;, on pages 1-15 in our
<I>
	Annual Report 2016
</I>
	.
</P>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LISTING>
<A NAME="FIS_LISTING"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_012">
</A>
	ITEM 9
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	THE
	OFFER AND LISTING
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; COLOR: #001965">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	A.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Offer and listing details
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The table below sets forth for the calendar
	periods indicated, in the first two columns, high and low prices for the B shares as reported by the Nasdaq Copenhagen and, in
	the third and fourth columns, high and low ADR prices as reported by the New York Stock Exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 2PT SOLID">
	Share price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 2PT SOLID">
	DKK per B share*
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 2PT SOLID">
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	USD per ADR*
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	2012
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	196.20
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	129.60
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	34.05
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	22.83
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	220.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	169.60
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	38.89
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	29.90
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	286.20
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	198.00
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	49.11
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	36.61
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	415.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	260.70
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	60.34
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	41.72
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	406.70
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	218.20
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	58.16
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	30.89
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 9&#9;THE OFFER AND LISTING
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 48%">
<FONT STYLE="FONT-SIZE: 10PT">
	1
<SUP>
	st
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	382.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	260.70
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	54.95
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
	41.72
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2
<SUP>
	nd
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	400.20
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	353.90
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	58.21
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	53.39
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	3
<SUP>
	rd
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	415.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	339.30
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	60.34
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	52.35
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	4
<SUP>
	th
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	403.30
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	346.00
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	59.00
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	52.61
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	1
<SUP>
	st
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	406.70
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	305.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	58.16
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	46.17
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	2
<SUP>
	nd
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	380.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	315.30
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	57.81
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	50.26
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	3
<SUP>
	rd
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	384.80
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	274.30
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	57.41
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	41.27
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	4
<SUP>
	th
</SUP>
	Quarter
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	288.90
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	218.20
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	41.96
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	30.89
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	August 2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	384.80
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	306.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	57.41
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	45.80
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	September 2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	317.70
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	274.30
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	46.55
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	41.27
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	October 2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	288.90
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	224.20
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	41.96
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	35.13
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	November 2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	243.50
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	218.20
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	35.96
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	30.89
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	December 2016
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	258.00
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	233.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	36.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	33.38
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	January 2017
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	261.70
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	238.40
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	37.08
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	34.58
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	February 1 2017
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	251.40
</TD>
<TD STYLE="FONT-WEIGHT: NORMAL; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	246.30
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	36.71
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	35.65
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	*) Following
	the change in trading units as of January 2, 2014, all quotes for 2012 to 2013 are restated to reflect the new trading unit of
	DKK 0.2 per B share and a ratio of B shares to ADRs of 1:1.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to our
<I>
	Annual Report
	2016
</I>
	&lsquo;Shares and capital structure&rsquo; on pages 44-45.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Plan of distribution
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Markets
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s share capital consists
	of A shares and B shares. As described above, the A shares are owned by the Novo Nordisk Foundation through its wholly-owned subsidiary
	Novo A/S and are not listed or traded on any stock exchange. The B shares have been publicly traded since 1974 and have been listed
	on Nasdaq Copenhagen since that time. The Nasdaq Copenhagen is the main trading market for the B shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	American Depositary Receipts representing
	the B shares (&lsquo;ADRs&rsquo;), as evidenced by American Depositary Receipts issued by JP Morgan Chase Bank of New York, as
	the Depositary, have been listed on the New York Stock Exchange since 1981. As of December 31, 2016, 208,409,325 B share equivalents
	(representing 10% of the outstanding B shares, adjusted for the treasury shares) were held in the form of ADRs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Selling shareholders
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	E.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Dilution
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	F.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Expenses of the issue
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_LISTING>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_ADDITIONAL_INFORMATION>
<A NAME="FIS_ADDITIONAL_INFORMATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_013">
</A>
	ITEM 10
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	ADDITIONAL
	INFORMATION
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	A.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Share capital
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	B.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Memorandum and articles of association
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This section summarizes certain material
	provisions of Novo Nordisk A/S&rsquo;s Articles of Association, certain other constitutive documents and relevant Danish corporate
	law. See Exhibit 1.1 to this Form 20-F for a translation into English language of the Articles of Association.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	General
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk A/S is a limited liability
	company organized under the laws of Denmark and registered with the Danish Business Authority under CVR number 24256790. Novo Nordisk
	A/S&rsquo;s objectives are to carry out research and development and to manufacture and commercialize pharmaceutical, medical and
	technical products and services as well as any other activity related thereto as determined by its Board of Directors. It strives
	to conduct its activities in a financially, socially, and environmentally responsible way. Novo Nordisk A/S's objectives are set
	out in Article 2 of its Articles of Association.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Powers of the Board
	of Directors
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All members of the Board of Directors have
	equal voting rights, and all resolutions are passed by a simple majority of votes. However, in the event of a tie, the Chairman
	shall have the casting vote. The Board of Directors forms a quorum when at least a majority of its members is present.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	According to the Danish Companies Act,
	no member of the Board of Directors or the Executive Management may take part in the consideration of any business involving agreements
	between any member of the group and himself, legal actions brought against himself, or any business involving agreements between
	any member of the Group and any third party or legal actions brought against any third party, if he has a major interest therein
	that might conflict with Novo Nordisk A/S&rsquo;s interests. The Danish Companies Act also prohibits Novo Nordisk A/S from granting
	loans or providing securities to any member of the Board of Directors and anyone particularly close to such a member of the Board
	of Directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The remuneration of the Board of Directors
	must be approved by Novo Nordisk A/S&rsquo;s shareholders at the Annual General Meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	According to Novo Nordisk A/S&rsquo; Articles
	of Association a person cannot be nominated for election or re-election if such person has reached the age of 70 at the time of
	the General Meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Rights, restrictions
	and preferences attaching to the shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the shareholders at an Annual General
	Meeting approve a recommendation by the Board of Directors to pay dividends, dividends shall be distributed as follows: a priority
	dividend of 1/2% of the nominal share capital to the holders of A shares and then up to a dividend of 5% to the holders of B shares.
	Any distribution of additional dividends shall be subject to the provision that the holders of A shares shall never receive a total
	dividend exceeding the percentage rate of the dividend paid to the holders of B shares. A shares take priority for dividends below
	0.5%. B shares take priority for dividends between 0.5% and 5. However, in practice, A shares and B shares receive the same amount
	of dividends per share of DKK 0.01. Dividends on A shares shall be remitted to the shareholders at the addresses entered in the
	Company&rsquo;s Register of Shareholders as at the date of the Annual General Meeting. Dividends on B shares shall be paid with
	fully discharging effect for the Company through a central securities depository and an account-holding bank to shareholders registered
	by VP Securities at the time of payment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At the Annual General Meeting in March
	2015, the Board of Directors was granted authority to distribute extraordinary dividends. This authority has been included in the
	Articles of Association of Novo Nordisk A/S. Hence the Board of Directors has been granted authority to pay interim dividends without
	obtaining specific approval from the Annual General Meeting. Any Board resolution to pay extraordinary dividends must be accompanied
	by a balance sheet showing that sufficient funds are available for distribution. An authorized auditor must review the balance
	sheet.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to the preference mechanism described
	above, the A shares and the B shares rank as equal in the event of a return on capital by the company. Upon a winding-up, liquidation
	or otherwise, the B shares rank ahead of the A shares with regard to payment of each share&rsquo;s nominal amount. All shares rank
	as equal in respect of further distributions from a winding-up.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Each A share of DKK 0.20 carries 200 votes
	and each B share of DKK 0.20 carries 20 votes at the General Meeting. A shares are non-negotiable instruments whereas B shares
	are negotiable instruments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The holders of A shares have a pro-rata
	right of first refusal with regard to any A shares sold by another shareholder. However, currently all A-shares are owned by Novo
	A/S and according to the Articles of Association of Novo A/S, the A shares cannot be divested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The share capital has been fully paid up
	and shareholders are not liable to further capital calls by Novo Nordisk A/S. No shareholder shall be obliged to have his shares
	redeemed in whole or in part. There is no sinking fund provision in the Articles of Association. There is no provision in the Articles
	of Association discriminating against any existing or prospective holder of such securities as a result of such shareholder owning
	a substantial number of shares. The members of the Board of Directors do not stand for reelection at staggered intervals and there
	is no cumulative voting arrangement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Changes in shareholders&rsquo;
	rights
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Changes in the rights of holders of A shares
	or B shares require an amendment of the Articles of Association. Unless stricter requirements are made under the Danish Companies
	Act for any such resolution to be passed, (i) at least 2/3 of the total number of votes in Novo Nordisk A/S shall be represented
	at the General Meeting, and (ii) at least 2/3 of the votes cast and of the voting share capital shall vote in favor of such a resolution.
	If the quorum requirement in (i) is not fulfilled, the Board of Directors shall within two weeks convene another General Meeting
	at which the resolution may be passed irrespective of the number of votes represented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	General Meetings
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk A/S&rsquo;s General Meetings
	shall be held at a venue in the Capital Region of Denmark. The Annual General Meeting shall be held before the end of April in
	every year. Extraordinary General Meetings shall be held as resolved by the General Meeting or the Board of Directors, or upon
	the request of the auditors or shareholders representing in total at least 5% of the&nbsp;share capital. The Extraordinary General
	Meeting shall then be called not later than two weeks after receipt of such request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	General Meetings shall be called by the
	Board of Directors not earlier than five weeks and not later than three weeks prior to the General Meeting. The notice calling
	such General Meeting, stating the agenda for the meeting, shall be published on the Company&rsquo;s website: novonordisk.com (the
	contents of this website are not incorporated by reference into this Form 20-F). The notice convening the meeting shall also be
	forwarded in writing to all shareholders entered in the Register of Owners who have so requested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A shareholder&rsquo;s right to attend and vote at a General
	Meeting shall be determined by the shares or ADRs which such shareholder owns at the applicable record date. The Danish record
	date is one week prior to the General Meeting. Any shareholder who is entitled to attend the General Meeting is required to apply
	for an admission card to such General Meeting no later than three days prior to the date of such General Meeting. ADR holders who
	wish to attend the General Meeting in Denmark should contact Kasper Veje, Investor Relations, tel + 1 609-235-8567 or via e-mail
	to kpvj@novonordisk.com.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The shares held by each shareholder at
	the Danish record date shall be calculated based on the registration of the shareholder&rsquo;s shares in the Register of Owners
	as well as any notification received by the Company with respect to registration of shares in the Register of Owners, which have
	not yet been entered in the Register of Owners.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Ownership restrictions
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no limitations on the rights
	of non-resident or foreign owners to hold or vote the shares imposed by the laws of Denmark, Novo Nordisk A/S&rsquo;s Articles
	of Association, or any other of its constituent documents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Change of control
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There is no provision in the Articles of
	Association, nor any other constituent document, that would have an effect of delaying, deferring or preventing a change in control
	of Novo Nordisk A/S and that would operate only with respect to a merger, acquisition or corporate restructuring involving the
	company (or any of its subsidiaries). However, based on the current shareholder structure, the voting rights held by holders of
	A shares outlined above afford the Novo Nordisk Foundation, acting through its wholly-owned subsidiary Novo A/S, to have veto power
	against any change of control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Ownership disclosure
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	According to the Danish Securities Trading
	Act and the Danish Companies Act, shareholders of Novo Nordisk A/S must notify the Danish Financial Supervisory Authority and Novo
	Nordisk A/S of their ownership if they own 5% or more of the voting rights or share capital. Also, shareholders must notify changes
	in holdings if thresholds of 5%, 10%, 15%, 20%, 25%, 50% or 90% and 1/3 and 2/3 of the voting rights or share capital are crossed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Changes in capital
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk A/S&rsquo;s Articles of Association
	do not contain conditions governing changes in the capital more stringent than those contained in the Danish Companies Act.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	C.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Material contracts
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There have been no material contracts outside the ordinary course
	of business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	D.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Exchange controls
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no governmental laws, decrees,
	or regulations in Denmark (including, but not limited to, foreign exchange controls) that restrict the export or import of capital,
	or that affect the remittance of dividends, interest or other payments to non-resident holders of the B shares or the ADRs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no limitations on the right
	of non-resident or foreign owners to hold or vote the B shares or the ADRs imposed by the laws of Denmark or the Articles of Association
	of the Company.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	E.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Taxation
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Danish Taxation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following summary outlines certain
	Danish tax consequences to U.S. Holders (defined below):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<I>
	Withholding Tax
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Generally, Danish withholding tax is deducted
	from dividend payments to U.S. Holders at a 27% rate, the rate generally applicable to non-residents in Denmark without regard
	to eligibility for a reduced treaty rate. Under the current Convention between the Government of the United States of America
	and the Government of the Kingdom of Denmark for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect
	to Taxes on Income (the &lsquo;Current Convention&rsquo;), however, the maximum rate of Danish tax that may be imposed on a dividend
	paid to a U.S. Holder that does not have a &lsquo;permanent establishment&rsquo; (as defined therein) in Denmark is generally
	15% and, for certain pension funds, 0% (each, the &lsquo;Treaty Rate&rsquo;). U.S. Holders eligible for the Treaty Rate may apply
	to the Danish tax authorities to obtain a refund to the extent that the amount withheld reflects a rate in excess of the Treaty
	Rate (any such amount, the &lsquo;Excess Withholding Tax&rsquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any U.S. Holders of ADRs wishing to apply
	for a refund of Excess Withholding Tax will have to provide a Danish Claim for Refund of Danish Dividend Tax, a properly completed
	U.S. Internal Revenue Service Form 6166 and additional documentation including: proof of dividend received; proof of ownership
	of the ADR and eligibility for the dividend received and proof that the dividend received was reduced by an amount corresponding
	to the Danish withholding tax. These documentation requirements may be expanded and may be subject to change. Refund claims must
	be filed within the three-year period following the date in which the dividend was paid in Denmark.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Information on tax reclaims, how they should
	be filed and the requisite tax forms may be obtained from:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	JPMorgan Chase Bank, N.A.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	c/o Globe Tax Services, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	1 New York Plaza, 34th Floor
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New York, New York 10004 USA
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Phone: +1 (800) 929 5484 or +1 (212) 747 9100
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	U.S. Holders should consult their tax advisers regarding dividend
	withholding tax refunds.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<I>
	Sale or Exchange of
	ADRs or B Shares
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any gain or loss realized on the sale or
	other disposition of ADRs or B shares by a U.S. Holder that is not either a resident of Denmark or a corporation that is doing
	business in Denmark is not subject to Danish taxation. In addition, any non-resident of Denmark may remove from Denmark any convertible
	currency representing the proceeds of the sales of ADRs or B shares in Denmark.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	U.S. Taxation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following summary outlines certain
	U.S. tax consequences for U.S. Holders (defined below) of owning and disposing of ADRs or B shares. A &lsquo;U.S. Holder&rsquo;
	is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ADRs or B shares that is eligible for the benefits
	of the Current Convention and is (i) a citizen or individual resident of the United States, (ii) a corporation, or other entity
	taxable as a corporation, created or organized in or under the laws of the United States or any political subdivision thereof,
	or (iii) an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. This discussion
	applies only to a U.S. Holder that holds ADRs or B shares as capital assets for U.S. tax purposes and does not apply to persons
	that own or are deemed to own 10% or more of Novo Nordisk voting stock. In addition, this discussion does not describe all of the
	tax consequences or potentially different tax consequences that may be relevant in light of the U.S. Holder&rsquo;s particular
	circumstances, including tax consequences applicable to U.S. Holders subject to special rules, such as certain financial institutions,
	entities classified as partnerships for U.S. federal income tax purposes, persons subject to the provisions of the U.S. Internal
	Revenue Code and Treasury regulations thereunder commonly known as the Medicare contribution tax, persons subject to the alternative
	minimum tax, or persons holding ADRs or B shares in connection with a trade or business conducted outside of the United States.
	This discussion is based, in part, on certain representations by the Depositary and assumes that each obligation under the deposit
	agreement will be performed in accordance with its terms. This discussion assumes that the Company is not, and will not become,
	a passive foreign investment company for U.S. federal income tax purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For U.S. federal income tax purposes, the
	holders of ADRs will be treated as the beneficial owners of the underlying B shares. Accordingly, no gain or loss for U.S. federal
	income tax purposes will be recognized if a U.S. Holder exchanges ADRs for the underlying B shares represented by those ADRs or
	B shares for ADRs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The U.S. Treasury has
	expressed concern that parties to whom American depositary receipts are released before shares are delivered to the depositary
	(referred to as a &lsquo;pre-release&rsquo;), or intermediaries in the chain of ownership between holders and the issuer of the
	security underlying the American depositary receipts, may be taking actions that are inconsistent with the claiming of foreign
	tax credits by holders of American depositary receipts. These actions would also be inconsistent with the claiming of the reduced
	rates of tax, described below, applicable to dividends received by certain non-corporate U.S. Holders. Accordingly, the creditability
	of Danish taxes, and the availability of the reduced tax rates for dividends received by certain non-corporate U.S. Holders, each
	described below, could be affected by actions taken by such parties or intermediaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<I>
	Taxation of Distributions
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For U.S. federal income tax purposes, distributions
	on ADRs or B shares received by U.S. Holders, before reduction for any Danish tax withheld, generally will be included in the U.S.
	Holder&rsquo;s income as foreign source dividend income and will not be eligible for the dividends-received deduction generally
	available to U.S. corporations. The amount of any dividend income paid in Danish kroner will be the U.S. dollar amount calculated
	by reference to the exchange rate in effect on the date of the U.S. Holder&rsquo;s, or, in the case of ADRs, the Depositary&rsquo;s
	receipt of the dividend regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend
	is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain
	or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into
	U.S. dollars after the date of receipt. U.S. Holders that receive a refund of Danish withholding tax after the dividend is received,
	as discussed above under the section &lsquo;Danish Taxation &ndash; Withholding Tax,&rsquo; may be required to recognize foreign
	currency gain or loss with respect to the amount of the refund. U.S. Holders should consult their tax advisers regarding whether
	any foreign currency gain or loss should be recognized in connection with distributions on ADRs or B shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to applicable limitations and conditions
	under U.S. federal income tax law and the discussion above regarding concerns expressed by the U.S. Treasury, dividends paid to
	certain non-corporate U.S. Holders may be taxable at favorable rates. In order to be eligible for the favorable rates, a non-corporate
	U.S. Holder must fulfill certain holding period and other requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subject to applicable limitations under
	U.S. federal income tax law and the discussion above regarding concerns expressed by the U.S. Treasury, a U.S. Holder may be eligible
	to credit against its U.S. federal income tax liability Danish taxes withheld from dividends on ADRs or B shares at a rate not
	exceeding the applicable rate under the Current Convention. Danish taxes withheld in excess of the applicable rate under the Current
	Convention will not be eligible for credit against a U.S. Holder&rsquo;s federal income tax liability. The rules governing foreign
	tax credits are complex and, therefore, U.S. Holders should consult their tax advisers regarding the availability of foreign tax
	credits in their particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Alternatively, subject to applicable limitations,
	U.S. Holders may elect to deduct Danish taxes withheld from dividend payments. An election to deduct foreign taxes instead of claiming
	a foreign tax credit must apply to all taxes paid or accrued in the taxable year to foreign countries and possessions of the United
	States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 10&#9;ADDITIONAL INFORMATION
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	Sale
	or Exchange of ADRs or B Shares
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A U.S. Holder will recognize capital gain
	or loss for U.S. federal income tax purposes on a sale or other disposition of ADRs or B shares, which will be long-term capital
	gain or loss if the U.S. Holder held the ADRs or B shares for more than one year. The amount of the gain or loss will equal the
	difference between the U.S. Holder&rsquo;s tax basis in the ADRs or B shares disposed of and the amount realized on the disposition,
	in each case as determined in U.S. dollars. Such gain or loss will generally be U.S. source gain or loss for foreign tax credit
	purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	Information
	Reporting and Backup Withholding
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Payments of dividends and sales proceeds
	that are made within the United States or through certain U.S. related financial intermediaries may be subject to information reporting
	and backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup withholding,
	the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The amount of any backup withholding from
	a payment to a U.S. Holder will be allowed as a credit against the holder&rsquo;s U.S. federal income tax liability and may entitle
	it to a refund, provided that the required information is timely furnished to the Internal Revenue Service.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Certain U.S. Holders who are individuals
	(and certain entities closely held by individuals) may be required to report information relating to securities issued by a non-U.S.
	person or foreign accounts through which such securities are held, subject to certain exceptions (including an exception for securities
	held in accounts maintained by U.S. financial institutions). U.S. Holders should consult their tax advisers regarding their possible
	reporting obligations with respect to the ADRs or B shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The foregoing sections offer a general
	description and U.S. Holders should consult their tax advisers to determine the U.S. federal, state, local and foreign tax consequences
	of owning and disposing of ADRs or B shares in their particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	F.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Dividends and paying agents
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	G.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Statement by experts
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	H.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Documents on display
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Documents referred to and filed with the
	SEC together with this Form 20-F can be read and copied at the SEC&rsquo;s public reference room located at 100 F Street, NE,
	Washington, DC 20549. Please call the United States Securities and Exchange Commission at 1-800-SEC-0330 for further information
	on the public reference rooms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Copies of the Form 20-F as well as our
<I>
	Annual Report 2016
</I>
	and
<I>
	Annual Report 2015
</I>
	can be downloaded from the Investors pages at novonordisk.com. The contents
	of this website are not incorporated by reference into this Form 20-F. The Form 20-F is also filed and can be viewed via EDGAR
	on www.sec.gov.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-STYLE: NORMAL">
	I.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
	Subsidiary information
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_ADDITIONAL_INFORMATION>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 11&#9;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_014">
</A>
	ITEM 11
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	QUALITATIVE
	AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	Financial
	exposure and financial risk management
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For a description and discussion of the
	Company&rsquo;s foreign exchange risk management, interest rate risk management, counterparty risk management and equity price
	risk management, reference is made to Note 4.2 &lsquo;Financial risks&rsquo; and &lsquo;Risk management&rsquo; on pages 40-43 in
	our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #009FDA">
<FONT STYLE="FONT-STYLE: NORMAL">
	Sensitivity
	analysis
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	When conducting a sensitivity analysis,
	the Group assesses the change in fair value on the market-sensitive instruments following hypothetical changes in market rates
	and prices. The rates used to mark-to-market the instruments are market data as of December 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Interest rate sensitivity
	analysis
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For information on Interest rate sensitivity analysis in the
	financial year of 2016, reference is made to Note 4.2 &lsquo;Financial risks&rsquo; in our
<I>
	Annual Report 2016
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="COLOR: #009FDA; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Foreign exchange sensitivity
	analysis
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For information on Foreign exchange sensitivity analysis in
	the financial year of 2016, reference is made to Note 4.2 &lsquo;Financial risks&rsquo; and &lsquo;Risk management&rsquo; on pages
	40-43 in our
<I>
	Annual Report 2016
</I>
	.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OTHER_SECURITIES>
<A NAME="FIS_OTHER_SECURITIES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_015">
</A>
	ITEM 12
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	DESCRIPTION
	OF SECURITIES OTHER THAN EQUITY SECURITIES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD NOWRAP STYLE="WIDTH: 4%">
<FONT STYLE="FONT-STYLE: NORMAL">
<A NAME="F20F_020917_HTM_A_016">
</A>
	Item 12A.
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 94%">
<FONT STYLE="FONT-STYLE: NORMAL">
	DEBT SECURITIES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD NOWRAP STYLE="WIDTH: 4%">
<FONT STYLE="FONT-STYLE: NORMAL">
<A NAME="F20F_020917_HTM_A_017">
</A>
	Item 12B.
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 94%">
<FONT STYLE="FONT-STYLE: NORMAL">
	WARRANTS AND RIGHTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD NOWRAP STYLE="WIDTH: 4%">
<FONT STYLE="FONT-STYLE: NORMAL">
<A NAME="F20F_020917_HTM_A_018">
</A>
	Item 12C.
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 94%">
<FONT STYLE="FONT-STYLE: NORMAL">
	OTHER SECURITIES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; COLOR: #001965; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD NOWRAP STYLE="WIDTH: 4%">
<FONT STYLE="FONT-STYLE: NORMAL">
<A NAME="F20F_020917_HTM_A_019">
</A>
	ITEM 12D.
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 94%">
<FONT STYLE="FONT-STYLE: NORMAL">
	American DEpositary shares
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s ADR program is administered
	by J.P. Morgan Depositary Receipts Group as Depositary, JPMorgan Chase Bank, N.A., 4 New York Plaza, New York, United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The ADRs are traded under the code NVO
	on the New York Stock Exchange and the underlying security is the Novo Nordisk B share, NOVOb on Nasdaq Copenhagen. Each ADR represents
	one deposited Novo Nordisk B share. One ADR carries the same voting rights as one Novo Nordisk B share. The Depositary distributes
	relevant notices, reports and proxy materials to the holders of the ADRs. When dividends are paid to shareholders, the Depositary
	converts the amounts into U.S. dollars and distributes the dividends to the holders of the ADRs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The holder of an ADR may have to pay the
	following fees and charges related to services in connection with the ownership of the ADR up to the amounts set forth in the table
	below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 12&#9;DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 55%; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-TRANSFORM: UPPERCASE; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Service
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 44%; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Fee
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Issuance or delivery of an ADR, surrendering of an ADR for delivery of a Novo Nordisk B share, cancellation of an ADR, including issuance, delivery, surrendering or cancellation in connection with&nbsp;&nbsp;share distributions, stock splits, rights and mergers
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	A maximum of USD 5.00 for each 100 ADRs (or portion thereof), to be paid to the Depositary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Distribution of dividend to the holder of the ADR
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	A maximum of USD 0.05 per ADR (or portion thereof), to be paid to the Depositary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Transfer of the Novo Nordisk B shares from the Danish custodian bank to the holder of the ADR&rsquo;s account in Denmark
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	USD 20.00 cabling fee per transfer, to be paid to the Depositary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Taxes and other governmental charges the holder of the ADR has to pay on any ADR or share underlying the ADR
</FONT>
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: #E0DED8; TEXT-ALIGN: LEFT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	As necessary
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	J.P. Morgan, as Depositary, has agreed
	to reimburse certain reasonable expenses related to Novo Nordisk&rsquo;s ADR program and incurred by Novo Nordisk in connection
	with the program. In the year ended December 31, 2016, the Depositary reimbursed USD 1,698,710 for costs related to investor relations
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #001965">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_OTHER_SECURITIES>
</EFX_PART_I>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<EFX_DEFAULTS>
<A NAME="FIS_DEFAULTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 13&#9;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_DEFAULTS>
</EFX_PART_II>
<EFX_PART_II>
<A NAME="FIS_PART_II_2"></A>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #001965">
<B>
<A NAME="F20F_020917_HTM_A_020">
</A>
	PART II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_021">
</A>
	ITEM 13
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	DEFAULTS,
	DIVIDEND ARREARAGES AND DELINQUENCIES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_MATERIAL_MODIFICATIONS>
<A NAME="FIS_MATERIAL_MODIFICATIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_022">
</A>
	ITEM 14
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	MATERIAL
	MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	None.
</P>
</EFX_MATERIAL_MODIFICATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_023">
</A>
	ITEM 15
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	CONTROLS
	AND PROCEDURES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Evaluation of disclosure
	controls and procedures
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk maintains disclosure controls
	and procedures that are designed to ensure that information required to be disclosed in reports that Novo Nordisk files or submits
	under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods
	specified in the rules and forms of the United States Securities and Exchange Commission, and that such information is accumulated
	and communicated to management of the Company, including the Chief Executive Officer and Chief Financial Officer, as appropriate
	to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk Management, including the
	Chief Executive Officer and Chief Financial Officer, evaluated the Company&rsquo;s disclosure controls and procedures as of December
	31, 2016. Based on this evaluation, the Company&rsquo;s Chief Executive Officer and Chief Financial Officer concluded that as of
	December 31, 2016, the Company&rsquo;s disclosure controls and procedures were effective at the reasonable assurance level.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In designing and evaluating the disclosure
	controls and procedures, Management recognized that any controls and procedures, no matter how well designed and operated, can
	provide only reasonable assurance of achieving the desired control objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Report of Novo Nordisk
	Management on Internal Control over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s Management is responsible
	for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
	is a process designed by, or under the supervision of, the Chief Executive Officer and Chief Financial Officer, and effected by
	the Company&rsquo;s Board of Directors, Management and other personnel to provide reasonable assurance regarding the reliability
	of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued by the
	IASB and as endorsed by the European Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because of its inherent limitations, internal
	control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
	to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
	of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk Management, including the
	Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&rsquo;s internal control over financial
	reporting as of December 31, 2016, using the criteria established in the
<I>
	Internal Control &ndash; Integrated Framework (2013)
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (&lsquo;COSO&rsquo;). Based on this assessment,
	Novo Nordisk Management, including the Chief Executive Officer and Chief Financial Officer, concluded that, as of December 31,
	2016, the Novo Nordisk Group&rsquo;s internal control over financial reporting was effective based on criteria stated in
<I>
	Internal
	Control &ndash; Integrated Framework (2013)
</I>
	issued by the COSO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_CONTROL_AND_PROCEDURES>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_AUDIT_COMMITTEE_EXPERT>
<A NAME="FIS_AUDIT_COMMITTEE_EXPERT"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 16A&#9;AUDIT COMMITTEE FINANCIAL EXPERTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The effectiveness of the Company&rsquo;s
	internal control over financial reporting as of December 31, 2016 has been audited by PricewaterhouseCoopers, Statsautoriseret
	Revisionspartnerselskab, Denmark, an independent registered public accounting firm, as stated in their report which appears on
	page 46 of this Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Changes in internal
	controls over financial reporting
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no changes in the Company&rsquo;s
	internal control over financial reporting that occurred during the year ended December 31, 2016 that have materially affected,
	or are reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_024">
</A>
	ITEM 16A
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	AUDIT
	COMMITTEE FINANCIAL EXPERTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Audit Committee is comprised of four
	members elected by the Board of Directors. Two members qualify as independent as defined by the SEC. One member is designated as
	chairman and two members are designated as Audit Committee Financial Experts as defined by the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2016, the Board of Directors re-elected
	the following individuals to the Audit Committee: Liz Hewitt (Audit Committee Chairman and Financial Expert), Jeppe Christiansen
	(Audit Committee Member and Financial Expert), Sylvie Gr&eacute;goire (Audit Committee Member) and Stig Str&oslash;b&aelig;k (Audit
	Committee Member). See Item 16D below. Financial expert Liz Hewitt is independent as defined by the SEC. Jeppe Christiansen, an
	additional financial expert, relies on an exemption from the independence standards.
</P>
</EFX_AUDIT_COMMITTEE_EXPERT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_CODE_OF_ETHICS>
<A NAME="FIS_CODE_OF_ETHICS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_025">
</A>
	ITEM 16B
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	CODE
	OF ETHICS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk has a vision and a set of
	essentials named the Novo Nordisk Way. The Novo Nordisk Way describes who Novo Nordisk as a company is, where Novo Nordisk wants
	to go and how its employees work. The Novo Nordisk Way is principle-based and describes corporate essentials and the required values
	and mindset of employees on business conduct and ethics including a number of the topics required by the Sarbanes&ndash;Oxley Act
	and the NYSE Listed Company Manual. In addition to the Novo Nordisk Way, a number of policies and related procedures have been
	established including a Business Ethics Code of Conduct and related business ethics requirements on how to conduct business in
	Novo Nordisk are outlined. The Novo Nordisk Way and our Business Ethics Code of Conduct apply to all employees in Novo Nordisk
	including the Chief Executive Officer and Chief Financial Officer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For further information on the Novo Nordisk Way, reference is
	made to &lsquo;Doing business the Novo Nordisk Way&rsquo; on pages 19-20 in our
<I>
	Annual Report 2016.
</I>
	The Novo Nordisk Way
	may be found on our website at novonordisk.com (the contents of the website are not incorporated by reference into this Form 20-F)
	and our Business Ethics Code of Conduct has been filed as Exhibit 11.1 hereto.
</P>
</EFX_CODE_OF_ETHICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_026">
</A>
	ITEM 16C
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	PRINCIPAL
	ACCOUNTANT FEES AND SERVICES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Reference is made to Note 5.5 &lsquo;Fee
	to statutory auditors&rsquo; in our
<I>
	Annual Report 2016
</I>
	regarding fees paid to our statutory auditors.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_ACCOUNTANT_FEES>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="FIS_EXEMPTIONS_FROM_LISTING"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 16D&#9;EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Statutory Audit Fees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Statutory audit fees consist of fees billed
	for the annual audit of the Company&rsquo;s Annual Report, the financial statements of the Parent Company, Novo Nordisk A/S, and
	financial statements of wholly-owned affiliates including audit of internal controls over financial reporting (Sarbanes&ndash;Oxley
	Act, Section 404). The fees also include fees billed for other audit services, which are those services that only the statutory
	auditor can provide, and include the review of documents filed with the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Audit-Related Fees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fees for audit-related services consist
	of fees billed for assurance and related services that are related to the performance of the audit or review of the Company&rsquo;s
	social and environmental reporting included in our
<I>
	Annual Report 2016
</I>
	and also include consultations concerning financial
	accounting reporting standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Tax Fees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fees for tax advisory services include
	fees billed for tax compliance services, tax consultations, such as assistance and representation in connection with tax audits
	and appeals and transfer pricing.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Other Fees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fees for other services comprise fees billed for other permitted
	services such as compliance reviews in connection with healthcare laws and regulations and assessment of their impact on the distribution
	chain, review of IT security plans and preparation of Benchmark reports etc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Pre-approval policies
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Audit Committee assesses and pre-approves
	all audit and non-audit services provided by the statutory auditors. The pre-approval includes the type of service and a fee budget.
	Furthermore, the Audit Committee receives a quarterly update on actual services provided and fees realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_027">
</A>
	ITEM 16D
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	EXEMPTIONS
	FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk&rsquo;s ADRs are listed on
	the New York Stock Exchange, the corporate governance rules of which require a foreign private issuer such as Novo Nordisk to have
	an Audit Committee that satisfies the requirements of Rule 10A-3 under the U.S. Securities Exchange Act of 1934, as amended. These
	requirements include a requirement that the Audit Committee be composed of members that are &ldquo;independent&rdquo; of the issuer,
	as defined in the Rule, subject to certain exemptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Of the current members of Novo Nordisk&rsquo;s
	Audit Committee, Stig Str&oslash;b&aelig;k is a current employee of Novo Nordisk who has been elected to the Board of Directors
	by the employees pursuant to the Danish Companies Act (Selskabsloven) which requires any limited liability company with more than
	35 employees on average over a three-year period to organize a vote in which the employees are entitled to decide whether they
	would like employee representation on the Board of Directors. Stig Str&oslash;b&aelig;k is not an executive officer of Novo Nordisk.
	Accordingly, his service on the Audit Committee is permissible pursuant to the exemption from the independence requirements provided
	for by paragraph (b)(1)(iv)(C) of Rule 10A-3. In addition, one member, Jeppe Christiansen, serves as a board member of Novo A/S
	(the controlling shareholder of Novo Nordisk A/S), and relies on an exemption in paragraph (b)(1)(iv)(B) of Rule 10A-3. Novo Nordisk
	does not believe the reliance on such exemptions would materially adversely affect the ability of the Audit Committee to act independently
	and to satisfy the other requirements of the Rule 10A-3.
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PURCHASES_OF_EQUITY>
<A NAME="FIS_PURCHASES_OF_EQUITY"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 16E&#9;PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_028">
</A>
	ITEM 16E
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	PURCHASES
	OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Total Number
<BR>
	of Shares
<BR>
	Purchased (a)*
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Average Price
<BR>
	Paid per Share
<BR>
	in DKK (b)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Total Number
<BR>
	of Shares Purchased
<BR>
	as Part of Publicly
<BR>
	Announced Plans or
<BR>
	Programs
<BR>
	(c)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID; TEXT-ALIGN: RIGHT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	Maximum Approximate
<BR>
	Value of Shares that may
<BR>
	yet be purchased under
<BR>
	the Plans or Programs in
<BR>
	DKK
<BR>
	(d)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2015 repurchase program
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Status year end 2015**
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	43,582,251
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	365.48
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	43,582,251
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,571,609,801
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	January 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,985,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	377.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47,567,251
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	65,390,102
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	February 1, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	171,964
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	380.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47,739,215
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	Total***
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,739,215
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	366.57
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,739,215
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	0
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2016 repurchase program****
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	14,000,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	February 2-28, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,330,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	336.80
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,330,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	12,878,456,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	March 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,184,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	368.97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,514,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	11,703,649,480
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	April 1-30, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,794,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	367.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,308,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	10,311,048,099
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	May 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,800,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	361.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,108,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	9,298,872,931
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	June 1-30, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,338,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	355.69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,446,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	8,111,579,057
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	July 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,920,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	371.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,366,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	7,027,567,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	August 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,896,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	320.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,262,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	5,779,407,247
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	September 1-30, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,291,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300.23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,553,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	4,491,111,615
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	October 1-31, 2016****
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,272,334
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	268.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31,825,337
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	4,344,542,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	November 1-30, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,080,662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	230.51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,905,999
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	2,712,356,299
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	December 1-31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,837,608
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	247.52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,743,607
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,514,969,612
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	43,743,607
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	308.27
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	43,743,607
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,514,969,612
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	*) All shares
	purchased through a publicly announced program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	**) Shares
	purchased under 2015 repurchase program during 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	***) As of
	February 1, 2016, Novo Nordisk had repurchased a total of 47,739,215 B shares equal to a transaction value of DKK 17,499,999,226.
	The DKK 17.5 billion share repurchase program announced 30 January 2015 was thereby concluded.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	****) In
	October 2016 the DKK 14.0 billion share repurchase program announced February 2016 was increased by DKK 1 billion to DKK 15.0
	billion.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Note to column (a) and
	(d)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors has authorization
	from the annual shareholders&rsquo; meeting to acquire up to 10% of the share capital at the price quoted at the time of the purchase
	with a deviation of up to 10%. This authorization is renewed annually at the annual general meeting. If the limit of 10% is reached,
	a number of shares would have to be cancelled before further purchases can be made. The cancellation of shares must be approved
	by the shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under this authorization, a share repurchase
	program for 2015 of DKK 17.5 billion was completed in February 2016. A new share repurchase program for 2016 of DKK 14.0 billion
	initiated in February 2016, and increased by DKK 1 billion to DKK 15.0 billion in October 2016, was completed in January 2017.
	The shares have been purchased through a bank directly in the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Column (a) shows shares Novo Nordisk purchased
	as part of our share repurchase program initiated in February 2015 (completed in February 2016) and our share repurchase program
	initiated in February 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Notes to columns (c)
	and (d)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In order to maintain capital structure
	flexibility, the Board of Directors intends to propose at the Annual General Meeting on March 23, 2017, a reduction in the B share
	capital, by cancellation of 50 million shares (nominal value DKK 0.20) of current treasury B shares, to DKK 392,512,800. This would
	correspond to a 1.96% reduction of the total share capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_PURCHASES_OF_EQUITY>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="FIS_CHANGE_IN_ACCOUNTANT"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE; COLOR: #009FDA">
	ITEM 16F&#9;change in registrant&rsquo;s certifying accountant
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_029">
</A>
	ITEM 16F
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT;TEXT-TRANSFORM: UPPERCASE">
	change
	in registrant&rsquo;s certifying accountant
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
</EFX_CHANGE_IN_ACCOUNTANT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CORPORATE_GOVERNANCE>
<A NAME="FIS_CORPORATE_GOVERNANCE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_030">
</A>
	ITEM 16G
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT;TEXT-TRANSFORM: UPPERCASE">
	Corporate
	governance
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk A/S is a public limited company
	incorporated in Denmark and admitted to trading on Nasdaq Copenhagen. As a result, it follows the Danish Corporate Governance Recommendations
	as amended on May 6, 2013 (last updated in November 2014) in respect of its corporate governance practices. Novo Nordisk has ADRs
	listed on the New York Stock Exchange (the &ldquo;NYSE&rdquo;) and is therefore required to comply with U.S. Securities laws, including
	the Sarbanes-Oxley Act and the NYSE Corporate Governance Standards (the &ldquo;NYSE Standards&rdquo;) applicable to listed companies
	as described in the NYSE Listed Company Manual&rsquo;s section 303A. As a foreign private issuer, Novo Nordisk is permitted to
	follow the corporate governance practice of its home country in lieu of certain provisions of the NYSE Standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk complies with the requirements
	of the SEC and NYSE except that Novo Nordisk as a &ldquo;controlled company&rdquo; (a listed company of which more than 50% of
	the voting power for the election of directors is held by an individual, a group or another company) pursuant to section 303A.00
	of the NYSE Listed Company Manual is not obliged to comply with sections 303A.01 (majority independent directors), 303A.04 (nominating/corporate
	governance committee) and 303A.05 (compensation committee) of the NYSE Listed Company Manual.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Moreover, Novo Nordisk as a foreign private
	issuer is permitted to follow home country practice in lieu of sections 303A.02 (independence tests), 303A.03 (executive sessions),
	303A.07 (audit committee), 303A.08 (shareholder approval of equity compensation plans), 303A.09 (corporate governance guidelines),
	303A.10 (code of business conduct and ethics) and 303A.12 (a) (certification requirements).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Below is a list of practices followed by
	Novo Nordisk as a foreign private issuer that differ from certain corporate governance requirements under the NYSE Standards:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Independence requirements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the NYSE Standards, listed companies
	must have at least a majority of independent directors and no director qualifies as &ldquo;independent&rdquo; unless the board
	of directors affirmatively determines that the director has no material relationship with the listed company (either directly or
	as a partner, shareholder or officer of an organization that has a relationship with the company).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the Danish Corporate Governance Recommendations,
	at least half of the elected members of the Board, excluding any members that have been elected by employees of the company, must
	be independent. Employees are entitled to be represented by half of the total number of Board members elected at the general meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the NYSE Standards a director is
	not deemed independent if the director is, or has been within the last three years, an employee of the listed company, or an immediate
	family member is, or has been within the last three years, an executive officer, of the listed company. Rule 303A.02 defines &lsquo;listed
	company&rsquo;, for purposes of the independence standards, to include &lsquo;any parent or subsidiary in a consolidated group
	with the listed company or such other company as is relevant to any determination under the independence standards set forth in
	this Section 303A.02(b)&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; TEXT-TRANSFORM: UPPERCASE; COLOR: #009FDA">
	ITEM 16G&#9;Corporate governance
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Four employees have in accordance with
	the requirements in the Danish Companies Act been elected as Board members by the Danish employees of the Company. No Board member
	or the Board member&rsquo;s immediate family members have within the last three years been an employee or executive of Novo Nordisk
	A/S or any parent or subsidiary in a consolidated group with Novo Nordisk A/S or received any fees from Novo Nordisk A/S.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board has determined whether Board
	members qualify as independent under the Danish Corporate Governance Recommendations. The Board has also determined whether the
	Board members, who are members of the Audit Committee, qualify as independent under Rule 10A-3 in the Securities Exchange Act.
	Such determination is disclosed in the Annual Report. Further, the Annual Report provides detailed and individual information regarding
	the Board members, but it does not explicitly identify which Board members the Board considers independent under the NYSE Standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Remuneration Committee
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Pursuant to the NYSE Standards listed companies
	must have a compensation committee composed entirely of independent directors. Compensation committee members must satisfy the
	additional independence requirements specific to compensation committee membership set forth in section 303A.02(a)(ii). The NYSE
	Standards states that in affirmatively determining the independence of any director who will serve on the compensation committee
	of the listed company&rsquo;s board of directors, the board of directors must consider all factors specifically relevant to determining
	whether a director has a relationship to the listed company which is material to that director&rsquo;s ability to be independent
	from management in connection with the duties of a compensation committee member.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As a controlled company, Novo Nordisk A/S
	is exempt from the requirement to establish a separate compensation committee in the same manner as U.S. companies are. At a Board
	of Directors meeting immediately following the Annual General Meeting the members of the Remuneration Committee is elected. When
	electing the members the Board of Directors considers all factors relevant to determine whether the members of the Remuneration
	Committee have a relationship to Novo Nordisk A/S which is material to the director&rsquo;s ability to be independent from management
	when performing its duties. At least a majority of the members of a board committee shall qualify as independent as defined by
	the Danish Corporate Governance Standards. Under the Danish Corporate Governance Recommendations one member of the Remuneration
	Committee qualifies as independent and three members qualify as non-independent, including the chairman. Hence, the composition
	of the Remuneration Committee does not conform to the Danish Corporate Governance Recommendations. This is due to the fact that
	the Board of Directors finds that it is beneficial for Novo Nordisk that the composition of the Remuneration Committee allows for
	both the Chairmanship, which consists of two non-independent Board members and which historically was responsible for oversight
	of remuneration, as well as an employee representative, who also qualifies as a non-independent Board member, being on the Remuneration
	Committee while maintaining an operational structure of the Remuneration Committee with relative few members.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Nomination Committee
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the NYSE Standards listed companies
	must have a nominating/corporate governance committee composed entirely of independent directors, which requirement does not apply
	to Novo Nordisk A/S as a controlled company. The Novo Nordisk A/S Nomination Committee consists of two members who are independent,
	and two members who are non-independent, including the chairman. A majority of the members of a board committee shall qualify as
	independent as defined by the Danish Corporate Governance Recommendations. Hence, the composition of the Nomination Committee does
	not conform to the Danish Corporate Governance Recommendations. This is due to the fact that the Board of Directors finds that
	the composition of the Nomination Committee allows for both a representative of the majority shareholder, who qualifies as a non-independent
	Board member, as well as an employee representative, who also qualifies as a non-independent Board member, being on the Nomination
	Committee while maintaining an operational structure of the Nomination Committee with relative few members.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_CORPORATE_GOVERNANCE>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 16H&#9;MINE SAFETY DISCLOSURE
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Audit Committee
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under Section 303A.06 of the NYSE Standards,
	listed company audit committees must be composed entirely of independent directors as set out in section 303A.02 and, in the absence
	of an applicable exemption, Rule 10A-3(b)(1). The Novo Nordisk A/S Audit Committee has four members. Two of the members satisfy
	the independence requirements of Rule 10A-3(b)(1) of the Securities Exchange Act and section 303A.02 of the NYSE Listed Company
	Manual.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	One Audit Committee member is an employee
	representative relying on the exemption from the independence requirements in Rule 10A-3(b)(1) provided for by paragraph (b)(1)(iv)(C)
	of Rule 10A-3 and one Audit Committee member serves as board member of Novo A/S relying on the exemption provided for in paragraph
	(b)(1)(iv)(B) of Rule 10A-3. See Item 16D above for further details.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
	Further, Novo Nordisk&rsquo;s Audit Committee,
	is among other things, responsible for oversight of and reporting to the Board on the elements described in section 303A.07(b)(i)(A)
	of the NYSE Listed Company Manual. However, with respect to legal and regulatory requirements, the Audit Committee&rsquo;s oversight
	responsibility only includes oversight of compliance with legal and regulatory requirements relating to business ethics compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; COLOR: #009FDA">
<B>
	Equity-compensation plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
	Under Section 303A.08 of the NYSE Standards,
	shareholders must be given the opportunity to vote on all equity compensation plans and material revisions thereto, with certain
	limited exceptions. Novo Nordisk&rsquo;s Remuneration Principles are approved by the Annual General Meeting and describe the framework
	for incentive programs for the Board and Executive Management. All incentive programs offered to the Board and/or Executive Management
	shall comply with this framework. However, under Danish law, the practice of voting on equity-compensation plans is not contemplated
	and accordingly, equity compensation plans are only subject to shareholder approval if they result in the issuance of new shares
	(and not if treasury shares are used).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; COLOR: #009FDA">
<B>
	Code of business conduct
	and ethics
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 6.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under Section 303A.10 of the
	NYSE Standards, listed companies must adopt and disclose a code of business conduct and ethics for directors, officers and employees,
	and promptly disclose any waivers of the code for directors or executive officers. Novo Nordisk has a global framework of rules
	and guidelines, including but not limited to the Novo Nordisk Way and a Business Ethics Code of Conduct, which describe the corporate
	principles on ethical business conduct. While certain topics mentioned in the NYSE Listed Company Manual are addressed in this
	framework of rules and guidelines, there may be topics which are not covered.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 6.3PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; COLOR: #009FDA">
<B>
	CEO certification
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
	Under Section 303A.12(a) of the NYSE Standards,
	each listed company Chief Executive Officer must certify to the NYSE each year that he or she is not aware of any violation by
	the listed company of NYSE Standards, qualifying the certification to the extent necessary. Novo Nordisk has opted to follow Danish
	law and regulations which do not contemplate such certifications. However, in accordance with NYSE Standards, Novo Nordisk will
	notify the NYSE promptly in writing if it becomes aware of any non-compliance with NYSE Standards applicable to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_031">
</A>
	ITEM 16H
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	MINE
	SAFETY DISCLOSURE
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #001965">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_II>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 17&#9;FINANCIAL STATEMENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_FINANCIAL_STATEMENTS>
</EFX_PART_III>
<EFX_PART_III>
<A NAME="FIS_PART_III_2"></A>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; COLOR: #001965">
<A NAME="F20F_020917_HTM_A_032">
</A>
<B>
	PART III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<A NAME="F20F_020917_HTM_A_033">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	ITEM 17
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	FINANCIAL
	STATEMENTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	See response to Item 18.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
	&nbsp;
</P>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_034">
</A>
	ITEM 18
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	FINANCIAL
	STATEMENTS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The financial statements required by this
	item accompany this annual report in the form of our
<I>
	Annual Report 2016
</I>
	(see Item 19).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #009FDA; FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL; TEXT-TRANSFORM: NONE">
	Reconciliation
	of non-IFRS financial measures
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the Financial statements, Novo Nordisk
	discloses certain financial measures of the Group&rsquo;s financial performance, financial position and cash flows that reflect
	adjustments to the most directly comparable measures calculated and presented in accordance with IFRS. The inclusion of non-IFRS
	measures has been expressly permitted by the Danish Business Authorities and thereby exempted from the prohibition in Item 10(e)(1)(ii)(C)
	of Regulation S-K. However, these non-IFRS financial measures may not be defined and calculated by other companies in the same
	manner and may thus not be comparable with such measures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The non-IFRS financial measures presented
	in our
<I>
	Annual Report 2016
</I>
	are:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Free cash flow;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash to earnings;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Operating profit after tax to net operating
	assets;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Financial resources at the end of the
	year; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sales growth in local currencies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Free cash flow
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Novo Nordisk defines free cash flow as
	&lsquo;net cash generated from operating activities less net cash used in investing activities&rsquo; excluding &lsquo;Net change
	in marketable securities&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A positive free cash flow shows that the
	Group is able to finance its activities and that external financing is thus not necessary for the Group&rsquo;s operating activities.
	Therefore, management believes that this non-IFRS liquidity measure provides useful information to investors in addition to the
	most directly comparable IFRS financial measure &lsquo;Net cash generated from operating activities&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table shows a reconciliation
	of free cash flow to &lsquo;Net cash generated from operating activities&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	Reconciliation of free cash flow
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	DKK million
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Free cash flow
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	39,991
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,222
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	27,396
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Net purchase of marketable securities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(2,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,232
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	+
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net cash used in investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	6,790
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	6,098
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	2,064
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net cash generated from operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,314
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	38,287
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	31,692
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 18&#9;FINANCIAL STATEMENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Cash to earnings
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Cash to earnings is defined as &lsquo;free
	cash flow as a percentage of net profit&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management believes that Cash to earnings
	is an important performance metric because it measures the Group&rsquo;s ability to turn earnings into cash and is, therefore,
	in the eyes of management a meaningful measure for investors to understand the development of the Group&rsquo;s net cash generated
	from operating activities. Because management wants this measure to capture the ability of the Group&rsquo;s operations to generate
	cash, free cash flow is used as the numerator instead of net cash flow.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table shows the reconciliation
	of Cash to earnings to the most comparable IFRS financial measure &lsquo;Cash flow from operating activities/earnings in %&rsquo;:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	Reconciliation of cash to earnings
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	DKK million
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Free cash flow
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	39,991
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,222
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	27,396
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	/
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net profit (as reported in the Annual Report)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	37,925
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,860
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,481
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net cash generated from operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	105.4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	98.2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	103.5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Net cash generated from operating activites
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,314
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,287
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	31,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	/
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net profit (as reported in the Annual Report)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	37,925
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	34,860
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,481
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cash flow generated from operating activities / net profit in %
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	127.4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	109.8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	119.7
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Operating profit after
	tax to net operating assets
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Operating profit after tax to net operating
	assets is defined as &lsquo;operating profit after tax (using the effective tax rate) as a percentage of average inventories, receivables,
	property, plant and equipment, intangible assets and deferred tax assets less non-interest bearing liabilities including provisions
	and deferred tax liabilities (where average is the sum of above assets and liabilities at the beginning of the year and at year-end
	divided by two)&rsquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management believes Operating profit after
	tax to net operating assets is a useful measure in providing investors and management with information regarding the Group&rsquo;s
	performance. The calculation of the financial target Operating profit after tax to net operating assets is a widely accepted measure
	of earnings efficiency in relation to total capital employed. Management believes that the income level relative to total capital
	employed, as measured by Operating profit after tax to net operating assets, is an effective measure of increases or decreases,
	as the case may be, in shareholder value generation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table reconciles Operating
	profit after tax to net operating assets with &lsquo;Operating profit/equity in %&rsquo;, the most directly comparable IFRS financial
	measure:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	Reconciliation of Operating profit after tax to net operating assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	DKK million
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Operating profit after tax
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	38,407
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	39,654
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	/
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Average non-interest bearing balance sheet items
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	25,578
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,668
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,537
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Operating profit after tax to net operating assets (as reported in the Annual Report) in %
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	150.2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	148.7
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	101.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 18&#9;FINANCIAL STATEMENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-TOP: BLACK 2PT SOLID; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	Numerator
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Reconciliation of Operating profit after tax to Operating profit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Operating profit after tax
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	38,407
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	39,654
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	/
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	(1 minus effective tax rate) in %
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	79.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	80.2
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	77.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Operating profit (as reported in the Annual Report)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	49,444
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BACKGROUND-COLOR: WHITE">
	Denominator
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Reconciliation of Average non-interest bearing balance sheet items to Equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Non-interest bearing balance sheet items at the beginning of the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	26,505
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,830
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,243
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Non-interest bearing balance sheet items at the end of the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	24,651
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,505
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,830
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	/
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	2
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	=
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Average non-interest bearing balance sheet items as used in Operating profit after tax to net operating assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	25,578
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,668
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,537
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Non-interest bearing balance sheet items at the end of the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	24,651
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,505
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	26,830
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Investment in associated company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	809
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	811
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Other financial assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	1,388
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	1,339
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Marketable securities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	2,009
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	3,542
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	1,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Derivative financial instruments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	529
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	304
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	+
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Cash at bank and in hand
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	18,690
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	16,923
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	14,396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	Loans
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	-
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Current debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	(229
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(1,073
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(720
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Derivative financial instruments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	(2,578
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(1,382
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(2,607
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Equity (as reported in the Annual Report)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	45,269
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	46,969
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	40,294
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Operating profit (as reported in the Annual Report)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	48,432
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	49,444
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	34,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; VERTICAL-ALIGN: TOP">
	/
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equity (as reported in the Annual Report)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	45,269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	46,969
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	40,294
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID; VERTICAL-ALIGN: TOP">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Operating profit/Equity in %
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	107.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	105.3
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	85.6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	*) The effective
	tax rate in 2015 was impacted by 1.3% from the non-taxable income from partial divestment of NNIT A/S.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
	Financial resources
	at the end of the year
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Financial resources at the end of the year
	is defined as the sum of cash and cash equivalents at the end of the year, bonds with original term to maturity exceeding three
	months and undrawn committed credit facilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management believes that the Financial
	resources at the end of the year is an important measure of the Group&rsquo;s financial strength from an investor&rsquo;s perspective,
	capturing the robustness of the Group&rsquo;s financial position and its financial preparedness for unforeseen developments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 18&#9;FINANCIAL STATEMENTS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
	Reconciliation of financial resources at the end of the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	2016
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE; BORDER-TOP: BLACK 2PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	DKK million
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Financial resources at the end of the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	28,648
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	27,601
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	23,373
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	Marketable securities at the end of the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	(2,009
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(3,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(1,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Undrawn committed credit facilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	(8,178
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(8,209
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	(8,188
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	=
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; BORDER-BOTTOM: BLACK 1PT SOLID">
	Cash and cash equivalents at the end of the year (as reported in the Annual report)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #E0DED8">
	18,461
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #E0DED8">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	15,850
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	13,676
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: RED">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #009FDA">
<B>
	Sales growth in local
	currencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Sales growth in local currencies is defined
	as sales for the current year measured at prior year average exchange rates compared with sales for prior year measured at prior
	year average exchange rates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Management believes that the sales growth
	in local currencies is relevant information for investors in order to understand the underlying development in sales by adjusting
	for the impact of currency fluctuations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 19&#9;EXHIBITS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965; MARGIN-TOP: 0; MARGIN-BOTTOM: 6PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 55PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_035">
</A>
	ITEM 19
</FONT>
</TD>
<TD STYLE="WIDTH: 5PT">
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 12PT">
	EXHIBITS
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #001965">
<B>
<U>
	a. Annual Report
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following pages from our
<I>
	Annual
	Report 2016
</I>
	, furnished to the SEC on Form 6-K, dated February 9, 2017, are incorporated by reference into this Form 20-F.
	The content of websites, scientific articles and other sources referenced on these pages are not incorporated by reference into
	this Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: RIGHT; TEXT-INDENT: 14.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #009FDA">
<B>
<U>
	Page(s)
	in the Annual Report
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #002060">
<B>
	Management Discussion and Analysis
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accomplishments and results 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1-15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our business
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	16-43
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pipeline overview
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	20-21
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk management
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40-43
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Shares and capital structure
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	44-45
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Corporate governance
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46-49
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Remuneration
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	50-53
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Board of Directors
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	54-55
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive Management
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	56
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #002060">
<B>
	Consolidated Financial Statements
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Income statement and Statement of comprehensive income for the years ended 31 December 2014, 2015 and 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	58
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Balance sheet as of 31 December 2015 and 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Statement of cash flows for the years ended 31 December 2014, 2015 and 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Statement of changes in equity at 31 December 2014, 2015 and 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	61
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Notes sections in the Consolidated financial statements
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	62-96
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Companies in the Novo Nordisk Group
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	95
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #002060">
<B>
	Consolidated Social Statement
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	New patent families (first filings)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	101
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #002060">
<B>
	Management Statement
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Statement by the Board of Directors and Executive Management on the Annual Report
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	107
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 73%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 148.85PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	ITEM 19&#9;EXHIBITS
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #001965">
<B>
<U>
	b. Exhibits
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	List of exhibits:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #009FDA">
<B>
<U>
	Exhibit
	No.
</U>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #009FDA">
<B>
<U>
	Description
</U>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #009FDA">
<B>
<U>
	Method of filing
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Articles of Association of Novo Nordisk A/S
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to the Registrant&rsquo;s Report furnished to the SEC on Form 6-K on March 21, 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Companies in the Novo Nordisk Group
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to page 95 of our
<I>
	Annual Report 2016
</I>
	filed on Form 6-K dated February 9, 2017.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Novo Nordisk Business Ethics Code of Conduct
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Filed together with this Form 20-F for 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Lars Fruergaard J&oslash;rgensen, President and Chief Executive Officer of Novo Nordisk, pursuant to Section 302 of the Sarbanes&ndash;Oxley Act of 2002.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Filed together with this Form 20-F for 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Jesper Brandgaard, Executive Vice President and Chief Financial Officer of Novo Nordisk, pursuant to Section 302 of the Sarbanes&ndash;Oxley Act of 2002.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Filed together with this Form 20-F for 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Certification pursuant to 18 U.S.C. Section 1350, as
	adopted pursuant to Section 906 of the Sarbanes&ndash;Oxley Act of 2002.
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Filed together with this Form 20-F for 2016.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Extracts from Registrant&rsquo;s Annual Report for the fiscal year ended December 31, 2016.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to the portions of Registrant&rsquo;s Report furnished to the SEC on Form 6-K on February 9, 2017 identified in Item 19.a of this Form 20-F.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.2
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Extracts from Registrant&rsquo;s Annual Report for the fiscal
	year ended December 31, 2015.
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Incorporated by reference to the portions of the Registrant&rsquo;s
	Report furnished to the SEC on Form 6-K on February 10, 2016 identified in Item 19.a of the Form 20-F filed on February 10, 2016.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.3
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consent of independent registered public accounting firm.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Filed together with this Form 20-F for 2016.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_III>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	Report of Independent Registered Public Accounting Firm
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-TRANSFORM: UPPERCASE; TEXT-INDENT: -70.9PT">
<FONT STYLE="FONT-SIZE: 12PT">
	Report
	of Independent Registered Public Accounting Firm
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To the Board of Directors and Shareholders
	of Novo Nordisk A/S
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the consolidated financial
	statements listed in the index appearing under Item 19(a) present fairly, in all material respects, the financial position of Novo
	Nordisk A/S and its subsidiaries at 31 December 2016 and 31 December 2015, and the results of their operations and their cash flows
	for each of the three years in the period ended 31 December 2016 in conformity with International Financial Reporting Standards
	as issued by the International Accounting Standards Board and in conformity with International Financial Reporting Standards as
	adopted by the European Union. Also in our opinion, the Company maintained, in all material respects, effective internal control
	over financial reporting as of 31 December 2016, based on criteria established in
<I>
	Internal Control - Integrated Framework (2013)
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible
	for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the
	effectiveness of internal control over financial reporting, included in the Report of Novo Nordisk Management on Internal Control
	over Financial Reporting, appearing under Item 15. Our responsibility is to express opinions on these financial statements and
	on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance
	with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether
	effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements
	included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the
	accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation.
	Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting,
	assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
	control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the
	circumstances. We believe that our audits provide a reasonable basis for our opinions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A company&rsquo;s internal control over
	financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s
	internal control over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of records
	that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide
	reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
	generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
	authorizations of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or
	timely detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect
	on the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because of its inherent limitations, internal
	control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
	to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
	of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ PricewaterhouseCoopers
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Statsautoriseret Revisionspartnerselskab
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Bagsv&aelig;rd, Denmark&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	February 1, 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: #009FDA">
	SIGNATURES
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="COLOR: #001965; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 70.9PT">
<FONT STYLE="FONT-SIZE: 12PT">
<A NAME="F20F_020917_HTM_A_036">
</A>
	SIGNATURES
</FONT>
</TD>
<TD>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Registrant hereby certifies that it
	meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual
	Report on its behalf.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOVO NORDISK A/S
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Lars Fruergaard J&oslash;rgensen
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Jesper Brandgaard
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Name:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 40%">
	Lars Fruergaard J&oslash;rgensen
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Name:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 40%">
	Jesper Brandgaard
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Title:
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	President and Chief Executive
	Officer
</P>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Executive Vice President
	and Chief Financial Officer
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Bagsv&aelig;rd, Denmark&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Dated: February 9, 2017
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 13.5PT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	47
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #001965">
	Novo
	Nordisk
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; COLOR: #009FDA">
	Form 20-F
	2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<HR NOSHADE SIZE="4" STYLE="COLOR: BLACK; WIDTH: 100%; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
</EFX_SIGNATURES>
<P STYLE="MARGIN: 0">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage49"></A>
<A NAME="EXH_111_HTM"></A>
<EFX_EXHIBIT_11>
<A NAME="FIS_EXHIBIT_11"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	Exhibit 11.1
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_01.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Novo Nordisk Business Ethics Code ofConduct
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_02.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	DearColleagues, TheNovoNordiskWaydescribeswhoweare,wherewewanttogoand thevaluesthat characterise ourcompany. One ofourvaluesisthatwenevercompromiseonbusinessethics(NovoNordiskWay,Essential10). This means weapplyhigh integritystandardsglobally and acrossthevaluechaininoureffortsto create long-term businessvalue. Our integrity must never be open to doubt or put at risk. Violations of our integrity would undermine thetrustthatpatientsand societyplaceinus.Ultimately,thiscouldresultinlosingourlicensetooperate leaving usunable toprovideproductstopatientswhoselivesand wellbeing depend onthem. This Business Ethics Code of Conduct explains Novo Nordisk&#8217;s expectations ofyou. Iamconfident thatthisCodeand thesupporting BusinessEthicsComplianceFrameworkwill helpyouresolvethequestionsthatmayariseaspartofyourjob. PleasetaketimetoreadthisCode,keepitinmindand useittoguide yourdecisionsand actions. Bydoing so,youarelivingtheNovoNordisk Way. Sincerely, KimBundegaard Chief Compliance Officer andChair of Business Ethics Board
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_03.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Appliesto &#8226;This Code applies to all NovoNordisk employees. &#8226;Businesspartnerswhoact onourbehalfasThird PartyRepresentativesmustalsofollowthisCode. Roles andResponsibilities Employee &#8226;ReadthisCode,andapplyitsprinciplesinyourdailywork. &#8226;ReportpossibleoractualviolationsofthisCode. Manager &#8226;ReadthisCodeandapplyitsprinciplesinyourdailywork. &#8226;Leadbyexampleandneverignoreoracceptunethicalbehaviour. &#8226;EnsurethatemployeesreportingtoyouunderstandhowtoapplythisCodeintheirdailywork. &#8226;Ensure that relevant local limits andprocesses are established in your area to support compliance with thisCode. &#8226;Ensure that Third Party Representatives you select and engagein your area are identified, evaluated, trained and monitored, see section4. &#8226;ReportpossibleoractualviolationsofthisCode,seesection2. ALEXSILVERBERG Alex has diabetes type1 and lives inSweden
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_04.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Table ofContents Opening Remarks Appliesto Roles andResponsibilities 2 3 3 1. Our Commitment to BusinessEthics 5 2. Ask Questions and RaiseConcerns 6 3. Business Ethics in General Bribes and ImproperAdvantages Facilitation Payments Fraud ConflictofInterest Gifts, Hospitality and Entertainment Grants,Donations and Sponsorships Off-labelCommunication BooksandRecords 7 7 7 8 8 8 9 9 10 4. Business Ethics in Our Interactions withStakeholders PublicOfficials Healthcare Professionals and HealthcareOrganisations Patients and PatientOrganisations Third PartyRepresentatives 11 11 11 12 12 Definitions 13
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_05.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	1. Our Commitment to BusinessEthics Novo Nordisk&#8217;s Business Ethics Policy [1] statesthat: InNovoNordisk,wewillactwithintegrityinoureffortstodeliver competitive results. This means that wewill: &#8226; applyconsistentlyhigh businessethicsstandardsacrossthevaluechain &#8226; addressday-to-daydilemmas guided bytheNovoNordisk Way &#8226; betransparentaboutourbusinessdecisionsand practices &#8226; holdourselvesaccountable foracting withintegrityand incompliance with the UN GlobalCompact. Be transparentabout our business decisionsand practices This Codespellsoutinfurtherdetailwhatintegritymeans toNovoNordisk anditsetsaglobal standard. The global standard is the minimum that must be followed across Novo Nordisk. Insomecountries,locallaws, regulationsorindustrycodesmaybemorestringent thanthisCode.Wherethisisso,wefollowthemorestringentrules. Alltheprinciplesyouneedtoknowcanbefound inthisCode. Moredetailedrequirementsand resourcesareavailable atthe Business Ethics ComplianceFramework. We do not accept violations of this Code and the supporting Business Ethics ComplianceFramework.EmployeeswhoviolatethisCodewillbeheldaccountable and disciplinary actions will be issued in line with Novo Nordisk&#8217;s Disciplinary Sanction Guidelines and locallaw. Alltheprinciplesyouneedtoknowcanbefound inthisCode
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_06.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	AnopenandhonestdialogueisapreconditionforNovoNordisktomaintain and continuously strengthen ourintegrity. WhenyouhaveaquestionoraconcernaboutapotentialoractualbreachofthisCode, the right thing is to raise your question or concern to relevantpeople. First, talktoyourmanager aboutit.Ifyouarenotcomfortablewiththis,contact: &#8226; Local Legal andCompliance &#8226; HR &#8226; Business Ethics Compliance Office or Group InternalAudit. 2. Ask Questions and RaiseConcerns Employees and externals can also report concerns to our Compliance Hotlinevia the Internet or by phone. Nine language options are available. All reports are treated confidentially and you have the option to report anonymously. To contact our Compliance Hotline, use this link or visit the Business Ethics ComplianceFramework. Itisimportant thatyouknowthatNovoNordiskwillnotacceptany retaliationagainst anyonewhoraisesaconcerningood faith.Agood-faith reportisonethatyoubelieve tobetrueand thatyoudonotmakewiththeaimofharming others.Youdonothave toknowallthefacts, aslong asyoureportingoodfaith. For contact details, visitthe Business Ethics ComplianceFramework All reports are treated confidentially and you have the option toreport anonymously.
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_07.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	3. Business Ethics inGeneral Always report any facilitation payment made to the ComplianceHotline. Bribes and ImproperAdvantages NovoNordiskdoesnotacceptbriberyoranyotherformofcorrupt businessbehaviour. Wecomplywithalllawsonbriberyand corruptionsuchastheU.S.ForeignCorrupt PracticesAct,theU.K.BriberyActand localanti-corruptionlawsand industrycodes inthecountrieswhereweoperate. We do not offer, give or accept bribes or any form of improper advantage, and we donotallowotherstogivebribesonourbehalf. Thisappliesinallinteractionswith ourstakeholders. Bribesand improperadvantages canbemonetarysuchascashpayments orillegal rebates. But they also include non-monetary items such as improper gifts, meals, products, travel expenses, or other items that ultimately mean the transfer of something ofvalueinreturnforsomespecialconsideration. It doesnotmatterwhetheryouuseyourownprivatemoneyorNovoNordisk&#8217;s funds topayabribeorimproperadvantage. Bothareagainst thisCode. Keepinmindthatperceptionmattersand thatyourbehaviourcanbeconsidered abribeoranimproperadvantage regardlessofyourintention. FacilitationPayments Novo Nordisk prohibits facilitation paymentsworldwide. Facilitation payments are gifts or payments made to a public official to speed up an administrative or otherwise routine task that should be performed anyway.Examples include processing papers for customs clearance, issuing visas and other actions by anofficial. If you are asked to make a facilitation payment, refuse to pay. Only if there is a threat to your life or health, should a payment be necessary. Contact your manager to discuss the appropriate way to deal with the situation. Always report any facilitation payment made totheComplianceHotlineand ensurethatitisbookedasa&#8216;facilitation payment&#8217; in Novo Nordisk&#8217;sbooks. Novo Nordisk does not accept bribery or anyother form of corrupt business behaviour.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_08.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Fraud PreventinganddetectingfraudisapriorityforNovoNordisk. Youmustnotengage inanykindoffraud against NovoNordisk,anyofourbusiness partners or governmententities. The meaning of fraud varies from country to country, but generally, it means deliberately deceiving apersonorcompany tounjustlyobtainanunauthorised benefit, suchasmoney, property or services. Examplesare: &#8226; theftoffunds, inventoryoranyotherassetfromNovoNordisk, including false expensereports &#8226; manipulation of accounting information or financial statements &#8226; misuse or forgery of any document (for example records, data,accounts, expense claims orcontracts) Conflict ofInterest Personalinterestsmustnothaveorevenappeartohaveanundueinfluence on our professionaljudgment. Aconflictofinterest occurs when youhaveaprofessionalorpersonalinterest thatmay affect your ability to perform your job without bias. It may relate to your own personal interests,orthoseofafamily member,afriendoranotherentityyouareinvolvedwith. Often,aconflictofinterestcanberesolvedacceptably forbothyouand NovoNordisk. So, if you believe you are involved in an actual or potential conflict of interest, let your manager know immediately, so that an appropriate solution can be found. Managers mustensurethatemployeeswhohaveaconflictofinterestarenotinvolvedinrelevant decision-making. Gifts, Hospitality andEntertainment NovoNordiskdoesnotgiveoracceptgifts,hospitalityorentertainment that could raise concerns about ourintegrity. Keep in mind that when you give or accept gifts, hospitality and entertainment in interactionswithbusinesspartners,thiscouldleadtoaconflictofinterestand beseen as a bribeor improper advantage. To avoid this, youmust: &#8226; not ask for gifts, hospitality or entertainment from our current or potentialbusiness partners &#8226; ensurethatanyofferorreceiptofgifts, hospitalityorentertainment isofreasonable value, infrequent, relatedtoabusinesspurpose,customaryforthatbusinessrelation and culturalpractice,and inlinewithanylocalrequirements.Lavishorinappropriate gifts, hospitalityorentertainment areprohibited Novo Nordisk does not give or accept gifts, hospitality or entertainment thatcould raise concerns about our integrity.
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_09.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	&#8226; never invite or pay for expenses unrelated to business meetings, or related to spouses, family members or other companions. Likewise, you must not accept offersfrombusinesspartnerstopayforexpensesunrelatedtobusinessmeetings, or relating to your spouse, family members or othercompanions. Stricter rules apply for interactions with Public Officials, HealthcareProfessionals (HCPs) and Healthcare Organisations(HCOs). Grants, Donations andSponsorships NovoNordiskgivescontributionstoorganisationsinsupportofhealthcare, continuing medical education, research, or for charitable purposes in line with &#8216;Novo Nordisk Triple Bottom Linecommitment&#8217;. We never offer or give such contributions to unduly influence therecipients or to undermine theirindependence. To ensure this, remember that we never offer or give grants, donationsand sponsorships: &#8226; toindividuals &#8226; toimproperlyencourage orrewardprescription,recommendation, orpurchase ofNovoNordiskproductsortoinfluence regulatory,pricing, orreimbursement decisions &#8226; forthepurposeofpre-approvaloroff-labelpromotion(asexplainedbelow). If you receive a request for grants, donations and sponsorships, read and comply with the requirements at the Business Ethics ComplianceFramework &#8211;&#8216;Grants,DonationsandSponsorships&#8217;. Off-labelCommunication NovoNordiskpromotesitsproductsinaccordancewiththeapproved productlabel. We never engage in promotion of our products prior to marketing authorisation, nor dowepromoteourproductsforuseinindicationsthatarenotincludedintheproduct labelling approvedbylocalregulatoryauthorities.&#8216;Off-labelpromotion&#8217;,aswecallit, isprohibited. Information about products that have not yet been approved or information that is not consistent with approved product labelling may be provided only on request or to supportproperexchange ofscientificinformation&#8211;inbothcasesonlybyourmedically and scientifically qualifiedstaff. If you provide product information as part of your job, read and comply with the requirements at the Business Ethics Compliance Framework&#8211; &#8216;Off-labelCommunication&#8217;. Read and comply with the limitsand requirements applicable toyour area at the Business Ethics Compliance Framework&#8211; &#8216;Gifts, Hospitalityand Entertainment&#8217;.
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_10.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Books andRecords NovoNordiskmaintainsaccuratebooksandrecordsofourbusinessdealings. In this way, we can always trace how we make or receive payments and for whatreason. When you provide anything of value to a company, entity or individual outside the NovoNordiskgroup, makesurethattherecordedentryisbookedcorrectly and states the purpose, nature and participants related to such transaction, for example when settling expenses related to business travel inConcur. Do not create records that are false, incomplete, or altered or that do notreflect thetruenatureoftransactions.Thisisconsideredfraud and isnotaccepted. BeespeciallycautiouswhenitcomestotransfersofvaluetoHCPsand HCOs. This istoensurethatwecanreport and disclosesuchtransfersinlinewith our procedures,applicable locallaws, regulationsand industrycodes,seealsosection 4. Ifyouprocessorapprovepayments, readand complywiththerequirements and supporting guidance attheBusinessEthics ComplianceFramework &#8211;&#8216;Books andRecords&#8217;. Do not create records that are false,incomplete, or altered or that do not reflect the truenature of transactions. This is considered fraud andis notaccepted. Abdul Aziz Al-Armally Abdul has HaemophiliaA and lives inKuwait
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_11.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	4. Business Ethics in Our Interactionswith Stakeholders PublicOfficials Novo Nordisk interacts with Public Officials ethically, responsibly and transparently.Wenevergiveorofferanythingofvaluetoundulyinfluence a PublicOfficial. The term Public Official is broad. For example, it covers politicians, officers, and others employed in government departments, in companies owned or partially owned by a government and ininternational organisations. Mostmedical and scientific personnel are seen as Public Officials when they work in government-owned hospitals, clinics, universities or similar facilities. In many countries, Public Officials also include HCPs. It is important that you recognise that our interactions with Public Officials are subject to strict International laws and local rules in the countries where weoperate. If you interact with Public Officials, read and comply with therequirements and supporting guidance at the Business Ethics ComplianceFramework &#8211;&#8216;PublicOfficials&#8217;. Healthcare Professionals andHealthcare Organisations Novo Nordisk believes that interactions with HCPs and HCOs have a profound and positive impact on the quality of patient treatment andfuture innovations. We engage with HCPs and HCOs as part of our research and development activities, for example in clinical trials. We also sponsor and arrange meetings with HCPs to inform them about the medical aspects of our products, or to provide,exchange or obtain other scientific or educational input. Where allowed, we also give samples of Novo Nordisk products to HCPsto enable HCPs to familiarise themselves with ourproducts. All these interactions are based on a valid scientific/business purpose andin compliance with all laws andindustry codes. We never give or offer anything of value to Healthcare Professionals or Organisations to influence theirprescribing or purchasing decisions and we are transparentwith regard to ourcontributions.
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_12.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	We never give or offer anything of value to HCPs or HCOs to unduly influence their prescribing or purchasing decisions and we are transparent with regardto ourcontributions. If you interact with HCPs or HCOs, read and comply with therequirements and supporting guidance at the Business Ethics ComplianceFramework &#8211;&#8216;Interactions withHCPs/HCOs&#8217;. Patients and PatientOrganisations At Novo Nordisk we focus on doing what is best for the patient. We consider theexchangeofinformationwithpatientsandpatientorganisations tobevital for our continued improvement of products and treatments. Valuable insights can come from theserelationships. We comply with local and international laws, regulations and industrycodesand ensuretransparency and high ethical standards in our interactions with patients and patient organisations. In addition, we follow the codes developedby individual patient organisations and respect theirindependence. Ifyouinteractwithpatients and patient organisations, readand comply withthe requirements and supporting guidance at the Business Ethics Compliance Framework &#8211;&#8216;Patients and PatientOrganisations&#8217;. Third PartyRepresentatives Sometimeswehirecompaniesorindividualswhoarenotpartof Novo Nordisk to provide services for us and represent us in interactions withPublicOfficialsand/orHCPsorHCOs.For example,theymayrepresent us in public tenders, perform lobbying, marketing or sales promotional activitiesonourbehalfororganiseoureducationalmeetingsforHCPs. We call them &#8216;Third Party Representatives&#8217; or&#8216;TPRs&#8217;. Because Third Party Representatives represent Novo Nordisk in critical relationships, they may expose us to liability and reputational damage, if they do not follow our Business Ethics standards. Therefore, we require them to agree to follow thisCode. Before we engage certain high-risk Third Party Representatives, we evaluatetheir integrity based on information collected from various sources. We also educate them in the standards of thisCode. During the business relationship, we continually monitor our Third Party Representatives&#8217; compliance with this Code and the terms of the contract. If a Third Party Representative violates this Code, we will requestimmediate action. If necessary, we will terminate the business relationship. If you interact with Third Party Representatives, read and complywith the requirements and supporting guidance atthe Business Ethics Compliance Framework &#8211;&#8216;Third PartyRepresentatives&#8217;. If you interactwith Third Party Representatives, read and comply with the requirements and support- ing guidance at theBusiness Ethics Compliance Frame- work &#8211;&#8216;Third PartyRepre- sentatives&#8217;.
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/09/0001171843-17-000780_EXH111_13.JPG" ALT="">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT-SIZE: 1PX; COLOR: WHITE">
	Definitions This list contains definitions of abbreviations and terms used in thisdocument. Definition Tooffer, promiseorgiveanyundue advantage oranything ofvalue,directly orindirectly, toa public official, business partner or any person, to obtain or retain business or other improper businessadvantage. Any legal person that is a healthcare, medical or scientific association or organisation (regardless of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organisations), through which one or more Healthcare Professionals provide services. This definition also includes HealthcareInstitutions (HCI).Notethat themeaning of&#8216;HCO&#8217;/&#8217;HCI&#8217;mayvary from country tocountry. Anymember ofthemedical,dental, pharmacyornursing professions oranyother personwho, in the course of his/her professional activities, may prescribe, purchase, supply,recommend, or administer a medicinal product. This includesalso any official or employee of a government agency or other organisation (whether in the public or private sector) that may prescribe, purchase, supply or administer medicinal products. In somecases, HCPs may also be covered by the term &#8216;Public Officials&#8217; by international anti-corruption laws. Notethat themeaning of&#8216;HCP&#8217;mayvary from country to country (i)Anofficer oremployee orpersonacting inanofficial capacity for oronbehalf ofagovernment, including any government department, agency or instrumentality; (ii) an officer or employee or personacting inanofficial capacityfor oronbehalf ofapublic international organisation including any department, agency or instrumentality and any entity thereof; or (iii) a political party official, candidate for political office, or person acting in an official capacity of a political party official or candidate foroffice. A voluntary UN initiative based on commitments from companies to implement universal sustainability principles andtotakestepstosupport theUnited Nations&#8217;goals. NovoNordisk hasmadeacommitment tocomplywith theprinciples of theUNGlobalCompact. Principle 10 on anti-corruption states that &#8220;businesses should workagainst corruption inallitsform, including extortion andbribery.&#8221; Anycompanyorindividual that isnot part oftheNovoNordiskgroup but isengaged by Novo Nordisk to provide certain services and, as part of the performance ofsuch services, actsonbehalf oforintheinterest ofNovoNordisktowards PublicOfficialsand/or Healthcare Professionals/Healthcare Organisations. Guidance on how to identify if a current or potential business partner is a Third Party Representative is available at Business Ethics Compliance Framework (link) &#8211;&#8216;Third PartyRepresentatives&#8217;. Off-label promotion means any communication to an external audience that is designed topromote an off-label use of a product. Off-label use means any use of a product that is not consistent with the currently approved product labelling or any use of an unapproved product. Product means any NovoNordiskmedicinal product ormedicaldevice(approved orunapproved). The product labelling is the information on the package insert as approved by the appropriate regulatory authority. The meaning of promotion varies from country to country. In the EU, it is defined as &#8216;any form of door-to-door information, canvassing activity or inducement designed to promote the prescription, supply, sale or consumption of medicinalproducts&#8217;. Term Bribery HealthcareOrganisation (HCO) HealthcareProfessional (HCP) PublicOfficial UN GlobalCompact Third PartyRepresentative Off-labelpromotion
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_11>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage62"></A>
<A NAME="EXH_121_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	Exhibit 12.1
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 12PT">
	Certification on the effectiveness
	of disclosure controls and procedures in Form 20-F for 2016
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, Lars Fruergaard J&oslash;rgensen, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	I have reviewed this annual report on Form 20-F of Novo Nordisk A/S;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
	in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others
	within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Novo Nordisk A/S
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Novo All&eacute;
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Telephone:
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Internet:
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	2880 Bagsvaerd
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	+45 4444 8888
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	www.novonordisk.com
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	Denmark
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	CVR Number:
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	24 25 67 90
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
	the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
	and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
	in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered
	by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control
	over financial reporting; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or
	persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant
	deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
	likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud,
	whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
	control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: February 9, 2017&#9;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Lars Fruergaard J&oslash;rgensen
</FONT>
</TD>
<TD STYLE="WIDTH: 65%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
	Lars Fruergaard J&oslash;rgensen
<BR>
	President and Chief Executive Officer
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; COLOR: GRAY">
	Page 2 of 2
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage64"></A>
<A NAME="EXH_122_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12_2"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	Exhibit 12.2
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 12PT">
	Certification on the effectiveness
	of disclosure controls and procedures in Form 20-F for 2016
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, Jesper Brandgaard, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	I have reviewed this annual report on Form 20-F of Novo Nordisk A/S;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
	in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others
	within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Novo Nordisk A/S
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Novo All&eacute;
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Telephone:
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 7PT">
	Internet:
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	2880 Bagsvaerd
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	+45 4444 8888
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	www.novonordisk.com
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	Denmark
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	CVR Number:
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 7PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 7PT">
	24 25 67 90
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
	the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
	and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
	in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered
	by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control
	over financial reporting; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or
	persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant
	deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
	likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud,
	whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
	control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: February 9, 2017
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Jesper Brandgaard
</FONT>
</TD>
<TD STYLE="WIDTH: 65%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
	Jesper Brandgaard
<BR>
	Executive Vice President and
<BR>
	Chief Financial Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; COLOR: GRAY">
	Page 2 of 2
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; COLOR: GRAY">
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT; COLOR: GRAY">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage66"></A>
<A NAME="EXH_131_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	Exhibit 13.1
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	CERTIFICATION OF LARS FRUERGAARD J&Oslash;RGENSEN,
	CHIEF EXECUTIVE OFFICER OF NOVO NORDISK A/S, AND JESPER BRANDGAARD, CHIEF FINANCIAL OFFICER OF NOVO NORDISK A/S, PURSUANT TO SECTION
	18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	In connection with the Annual Report of Novo Nordisk A/S (the &quot;Company&quot;) on
	Form 20-F for the period ending December&nbsp;31, 2016, as filed with the Securities and Exchange Commission on the date hereof
	(the &quot;Report&quot;), the undersigned hereby certify that to the best of our knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Date: February 9, 2017
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 46%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Lars Fruergaard J&oslash;rgensen
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Jesper Brandgaard
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	Lars Fruergaard J&oslash;rgensen
<BR>
	President and Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD>
	Jesper Brandgaard
<BR>
	Executive Vice President and
<BR>
	Chief Financial Officer
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="FONT-WEIGHT: BOLD; WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 8PT">
	Novo Nordisk A/S
</FONT>
</TD>
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 8PT">
	Novo All&eacute;
</FONT>
</TD>
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 8PT">
	Telephone:
</FONT>
</TD>
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 8PT">
	Internet:
</FONT>
</TD>
<TD STYLE="WIDTH: 20%">
<FONT STYLE="FONT-SIZE: 8PT">
	CVR Number:
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	2880 Bagsvaerd
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	+45 4444 8888
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	www.novonordisk.com
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	24 25 67 90
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Denmark
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage67"></A>
<A NAME="EXH_153_HTM"></A>
<EFX_EXHIBIT_15>
<A NAME="FIS_EXHIBIT_15"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	Exhibit 15.3
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	Consent of independent registered
	public accounting firm
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	We hereby consent to the incorporation by reference in the Registration
	Statements on Form S-8 (No. 333-82318 and No. 333-83724) of Novo Nordisk A/S of our report dated February 1, 2017 relating to the
	Consolidated Financial Statements and the effectiveness of internal control over financial reporting, which appears in this Form
	20-F.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	/s/ PricewaterhouseCoopers
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Statsautoriseret Revisionspartnerselskab
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Copenhagen, Denmark
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	February 9, 2017
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_15>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
